

1 Appendix G: Network meta-analysis

Acknowledgements

The syntheses described in this document were conceptualised and implemented with the invaluable advice of the NICE clinical guidelines technical support unit (Nicky Welton, Sofia Dias, Edna Keeney).

Sylwia Bujkiewicz provided some useful comments on the use of a multivariate likelihood in an NMA.

Any errors that remain are the responsibility of the developers and the guideline committee.

G.1.2 Methods

G.1.13 General

- 4 All NMAs followed the generalised linear modelling framework recommended by the NICE
5 Decision Support Unit (see Technical Support Document 2 [Dias et al. 2011a]).
- 6 The choice of reference comparator – that is, the treatment with which all other treatments
7 are compared – within a network meta-analysis is mathematically arbitrary (DSU TSD2 [Dias
8 et al. 2011a]); however, computational efficiency is improved by selecting an option that is
9 ‘well connected’ in the network, with a good amount of data available. For this reason, the
10 reference treatment for all NMAs was ranibizumab 0.5 mg 1-monthly.

G.1.1.11 Basic model specification

12 Particular models fitted for specific datatypes are detailed below. However, all models shared
13 the same basic structure:

14 Fixed- and random-effects models were explored for relative treatment effects.

- 15 • In the fixed-effect model, a common effect is assumed for treatments across all trials and,
16 for all $j > 1$, the relative effect (δ) of the treatment (t) in arm j of trial i compared with the
17 treatment in arm 1 of trial i is estimated as the difference between the comparators in
18 each pair:

$$\delta_{i,j} = d_{t_{ij}} - d_{t_{i1}}, \quad (1)$$

19 with the d s representing the effect of each treatment relative to the ‘reference’ option in
20 the network – so, in the case of $t_{i1}=1$ (that is, the treatment in arm 1 of trial i is ranibizumab
21 0.5 mg 1-monthly), $d_{t_{i1}}=0$.

- 22 • In the random-effects model, trial-specific estimates of relative effect between each
23 treatment and the treatment in arm 1 are assumed to be exchangeable and drawn from a
24 shared distribution. In this implementation, normal distributions of treatment effects are
25 assumed, the mean ($d_{t_{ij}} - d_{t_{i1}}$) is specific to each pairwise comparison of interest and the
26 variance (σ^2) is assumed to be common to all comparisons. That is,

$$\delta_{i,j} \sim N(d_{t_{ij}} - d_{t_{i1}}, \sigma^2). \quad (2)$$

27 Trial-specific ‘baselines’, μ_i , are estimated as unrelated nuisance parameters, and combined
28 with relative effects so that the observed data (as transformed through an appropriate link

1 function; see below) in arm j of trial i (θ_{ij}) can be seen as a linear combination of these
2 parameters:

$$\theta_{ij} = \mu_i + \delta_{i,j}. \quad (3)$$

G.1.1.23 Meta-regression

4 Every treatment in every trial could be viewed as a combination of 3 factors: agent, dose and
5 treatment regimen. For all outcomes, models were explored that treated each treatment
6 option in the network as a discrete, mutually exclusive combination of these 3 things (for
7 example, bevacizumab 1.25 mg monthly -v- ranibizumab 0.5 mg monthly -v- ranibizumab
8 0.5mg PRN... and so on).

9 However, because there are shared features between the treatment regimens, we also
10 explored models in which identical intra-agent features of regimens were assumed to result
11 in identical effect modification across all agents, using a meta-regression approach (see
12 NICE Decision Support Unit Technical Support Document 3 [Dias et al. 2011b]). For
13 example, we fitted models in which the difference between PRN treatment and routine
14 monthly treatment was assumed to be the same for all agents. In this formulation, model (3)
15 is extended such that observed treatment effects are modelled as a combination of baseline,
16 agent-level treatment effect and effect of PRN administration:

$$\theta_{ij} = \mu_i + \delta_{i,j} + \beta(x_{i,j} - x_{i,1}), \quad (4)$$

17 Where β is the effect of PRN administration and $x_{i,j}$ and $x_{i,1}$ are dummy variables indicating
18 whether a PRN strategy was used in arm j and arm 1, respectively, of trial i . Clearly, in any
19 contrast for which both or neither arm have a PRN regimen, this term reduces to 0.

20 This framework could be extended to include as many covariates as the data will support.
21 We explored the impact that was made by including the following in this meta-regression
22 approach:

23 **Table 1: Potential meta-regression covariates**

Covariate	Definition
PRN	PRN (treatment as needed) compared with a routine monthly schedule. Note that this covariate applies to anti-VEGF strategies, only; all PDT regimens were given on a PRN basis, but were coded as 0 as there was no opportunity to differentiate between routine and PRN regimens (and, where evidence available, the degree of effect modification could easily be quite different). As a matter of principle, we would have been interested in exploring whether PRN regimens with different follow-up times have different results. However, no evidence was included that allowed us to test this, as all PRN regimens had similar follow-up frequencies (all were essentially monthly).
Loading	Supplementing a PRN schedule with an initial loading phase (invariably monthly injections in months 0, 1 and 2). Note that this covariate applies to PRN schedules only. Analogous loading phases were included in some of the RCTs exploring routine injections at greater than monthly intervals, and an attempt was made to model these separately; however, in that instance, there were insufficient data to be able to distinguish effects. For this reason, e.g., 3-monthly regimens with an initial loading phase are coded 0 for this covariate.
TREX	Treat-and-extend regimen compared with a routine monthly schedule.
PRNX	PRN-and-extend regimen compared with a routine monthly schedule. This appears in only 1 RCT (SALUTE 2015), in which the strategy (referred to as 'wait and extend') is compared with a conventional PRN approach (both using ranibizumab 0.5mg). Because there is only 1 datapoint, there is no material difference between including the arm as a separate node within the network and coding it as PRN with a covariate for PRNX. The latter approach has the small advantage that the estimated effect the PRNX regimen makes can be directly seen

Covariate	Definition
	rather than inferred from the difference between 2 nodes. In turn, this makes it easier to explore what the impact of such a regimen might be on agents other than ranibizumab.
Frequency (interval between injections in months)	<p>For 1 or more anti-VEGF agent, evidence was available on routine 1-monthly, 6-weekly, 2-monthly and/or 3-monthly administration frequencies. These were coded as 1, 1.5, 2 and 3, respectively, to provide a continuous estimate of effect modification for every month between injections over and above 1.</p> <p>The guideline committee suggested that there was a priori reason to imagine that frequency–response effects might plausibly be different between different anti-VEGF agents. Therefore, 3 different approaches to modelling frequency were explored. In model a, a single coefficient – assumed to be shared between all agents – was estimated. In model b, separate coefficients were estimated for each agent. In model c, 2 coefficients were used – 1 shared between bevacizumab and ranibizumab (which are pharmacologically very closely related) and a separate term for aflibercept. A fourth approach might be proposed, in which each treatment’s effect is modelled as belonging to a shared distribution; however, large quantities of data are typically required in order to estimate such a model or, alternatively, an informative prior has to be specified to limit the spread of the distribution to a plausible degree (and, in this relatively abstract case, it would have been difficult to elicit meaningful values for this even from the experienced members of the guideline committee).</p> <p>Once more, this covariate only applied to anti-VEGF treatments. Although all PDT regimens were provided on a 3-monthly (PRN) basis, they were coded as monthly for the purposes of these models, so that the effect of PDT-3-monthly-PRN, as a standalone node, would not influence estimation of frequency–response gradients for anti-VEGFs.</p>

1 Because there was relatively little variety in the doses used in trials, and it was not deemed
2 appropriate to assume that effect modification would be the same across agents on a
3 milligram-for-milligram scale, a similar approach was not explored for dose–response effects.
4 Therefore, we retained each agent–dose dyad as discrete nodes within the network in all
5 analyses. There was one exception to this rule: on the advice of the guideline committee, we
6 assumed 0.3 mg and 0.5 mg doses of ranibizumab were interchangeable, and combined
7 them into a single node. We tested this in a sensitivity analysis, which confirmed that model
8 fit was not improved by treating these doses as separate, with the addition of extra nodes
9 leading to inferior DIC; therefore, the committee's expectation was validated.

G.1.1.30 Prior distributions

- 11 Non-informative prior distributions were used in all models.
- 12 • Trial baselines and treatment effects were assigned $N(0, 100^2)$ priors.
- 13 • The between-trial standard deviations used in random-effects models were dependent on
14 the datatype:
- 15 ○ $U(0, 50)$ for continuous BCVA data (natural scale)
- 16 ○ $U(0, 10)$ for categorical BCVA data (probit scale)
- 17 ○ $U(0, 5)$ for dichotomous discontinuation data (log-odds scale)
- 18 • In categorical models
- 19 ○ inter-category intervals were given $U(0, 5)$ priors.
- 20 ○ inter-trial random-effects for inter-category intervals were given $U(0, 2)$ priors.
- 21 • In meta-regression models, all covariates were assigned $N(0, 1000)$ priors.

G.1.1.22 Model selection

23 Model selection was performed on the basis of multiple discriminatory variables.

- 1 • **Deviance information criterion** (DIC; Spiegelhalter et al. 2002): an estimate of deviance
2 that is ‘penalised’ according to the number of parameters in the model (adding parameters
3 to a model should increase its ability to predict known data; however, this may come at
4 the expense of reducing its ability to predict external datasets). A difference of least 3
5 points in DIC is commonly used to define meaningfully different models; we did not use
6 this as an absolute arbiter of superior fit, though it was still important to define clearly
7 different models.
- 8 • **Total residual deviance**: a calculation of the model’s ability to predict the individual
9 datapoints underlying it. In every iteration of the model sampling procedure, the amount
10 each model-estimated datapoint deviates from the observed evidence is calculated,
11 summed and averaged over all iterations. Each datapoint is expected to contribute
12 approximately 1 to the posterior mean deviance; therefore, the total residual deviance of a
13 well-fitting model will be approximately the same as the number of independent datapoints
14 in the model (DSU TSD2 [Dias et al. 2011a]).
- 15 • **SD of random-effects term (tau)**: where a random-effects model is fitted, the width of the
16 inter-study heterogeneity distribution estimated by the model is a reflection of
17 heterogeneity in the underlying data. Therefore, while not a measure of goodness of fit *per*
18 *se*, it is useful to consider as an indication of how broad a model is required to fit the data.
19 For example, if the introduction of a covariate results in a smaller inter-study random-
20 effects, term, it can be inferred that a proportion of inter-study heterogeneity has been
21 explained by the new term. Because inter-study heterogeneity is not modelled in fixed-
22 effects models (that is, tau is assumed to be 0), there is no analogous quantity that can be
23 used to compare different fixed-effects models.

24 Particular attention was paid to model selection for the most critical synthesis for the health
25 economic model – bivariate normal WMD at 12 and 24 months (see G.2.1.1.1.1). Once an
26 optimal model had been selected for this outcome, we took the view that it would be helpful
27 (and convenient for parameterising our HE model) to adopt a consistent specification for all
28 other models, provided it did not result in conspicuously worse fit than was available with
29 another choice. Therefore, we examined model fit statistics, in these other cases, with a view
30 to establishing whether it was clearly incorrect to support the globally preferred model, rather
31 than re-establishing whether that model should be preferred.

G.1.1.52 Baseline syntheses

33 While NMAs provide a coherent estimate of relative effect, it is often necessary to combine
34 these with an estimate of absolute effect in order to estimate expected outcomes of
35 treatment (most importantly, in the present context, in order to deploy outputs in a health
36 economic analysis). Put more simply, the NMAs tell us how much **more** or **less** likely people
37 are to experience the event of interest, given the treatment to which they have been
38 assigned, but additional evidence is necessary to estimate ‘more likely than **what?**’

39 To do this, we synthesised arm-level data from included RCTs, following the
40 recommendations of NICE DSU TSD5 (Dias et al. 2011c). Data from trials reporting the
41 effect of ranibizumab 0.5 mg monthly were pooled using the same Bayesian generalised
42 linear modelling framework that was used in the NMAs of treatment effect. Likelihoods and
43 link functions were as specified for the datatypes below. Prior distributions were identical to
44 those used in NMAs (see G.1.1.3). OpenBUGS code is provided in G.4.2.

G.1.1.55 Computation

46 Models were run in OpenBUGS 3.2.2. Code for all selected models is provided in G.4.

47 Results were reported summarising 10,000 samples from the posterior distribution of each
48 model, having first run and discarded 50,000 ‘burn-in’ iterations. Three separate chains with
49 different initial values were used.

- 1 Outputs from the chains, including autocorrelation plots, were visually inspected to assess
- 2 convergence. In some instances, it was necessary to introduce additional burn-in samples
- 3 and/or ‘thin’ posterior samples (e.g. by taking 1 in every 100 sampled values). In every case,
- 4 it was possible to produce well converged results in this way.

G.1.25 Continuous variables

6 The only continuous outcome of interest was absolute BCVA, for which mean change from
7 baseline to follow-up was the point of synthesis.

8 It is common, in such circumstances, to fit identity-link models, which rely on a normal
9 likelihood (see NICE DSU TSD2 [Dias et al. 2011a]). Although we assume, elsewhere in the
10 analysis undertaken for this guideline, that mean change in BCVA is likely to be normally
11 distributed, the synthesis model adopted here does not rely on this assumption; rather, it
12 assumes that the sample means are normally distributed (given sufficiently large samples,
13 this would be expected to be the case regardless of skewness in the underlying data,
14 according to the Central Limit Theorem).

15 However, in this case, we have reasonable amounts of 1-year and 2-year follow-up data,
16 which can be expected to be correlated. For that reason, we concluded it was superior to
17 perform synthesis in a single analysis, extending the simple continuous model to the
18 bivariate case, and estimating effects – and effect modifiers – for both timepoints at the same
19 time.

20 We are interested in estimating outcomes for time interval (0,1) and time interval (0,2). The
21 outcomes for interval (1,2) will also be of interest, especially for deployment in the health
22 economic analysis; however, this can be trivially inferred by deducting (0,1) from (0,2).

23 When the data are assembled, we have 2 distinct situations that need to be accounted for in
24 the same model.

25 **1-year RCTs** provide data on interval (0,1) only. Extending the notation of equations (1) and
26 (2) to encompass time-intervals, we have

$$\delta_{i,j,(0,1)} = d_{t_{ij,(0,1)}} - d_{t_{i1,(0,1)}}, \quad (5)$$

27 for the fixed-effects implementation. For the random-effects version, interval-specific inter-
28 study heterogeneity is modelled:

$$\delta_{i,j,(0,1)} \sim N \left(d_{t_{ij,(0,1)}} - d_{t_{i1,(0,1)}}, \sigma_{(0,1)}^2 \right). \quad (6)$$

29 An approach with a shared variance term for intervals (0,1) and (1,2) was explored, but
30 provided clearly inferior model fit than allowing separate variance terms in each interval.

31 **2-year RCTs** provide data on (0,1) and (0,2) and require a multivariate likelihood. Let
32 $m_{i,j,(0,1)}$ be the mean change for (0,1), with standard error $se_{i,j,(0,1)}$. Similarly, let $m_{i,j,(0,2)}$ be
33 the mean change for (0,2), with standard error $se_{i,j,(0,2)}$. Then the joint likelihood (Franchini et
34 al. 2012) is:

$$\begin{pmatrix} m_{i,j,(0,1)} \\ m_{i,j,(0,2)} \end{pmatrix} \sim N \left(\begin{pmatrix} \theta_{i,j,(0,1)} \\ \theta_{i,j,(0,2)} \end{pmatrix}, \begin{pmatrix} se_{i,j,(0,1)}^2 & se_{i,j,(0,1)}^2 \\ se_{i,j,(0,1)}^2 & se_{i,j,(0,2)}^2 \end{pmatrix} \right), \quad (7)$$

35 with $\theta_{i,j,(0,1)}$ and $\theta_{i,j,(0,2)}$ defined with interval-specific baselines and effects as per (3) (or (4)
36 in the case of a meta-regression model).

- 1 The model for $\delta_{i,j,(0,1)}$ is as per (5) and (6) for interval (0,1). For the interval (0,2), it is the
2 sum of the (0,1) effect and a new term for the (1,2) change. That is,

$$\delta_{i,j,(0,2)} = \delta_{i,j,(0,1)} + \delta_{i,j,(1,2)}, \quad (8)$$

- 3 with $\delta_{i,j,(1,2)}$ defined as the study-specific treatment effect over interval (1,2). In a fixed-effect
4 model, this is

$$\delta_{i,j,(1,2)} = d_{t_{ij,(1,2)}} - d_{t_{i1,(1,2)}} \quad (9)$$

- 5 and, in the random-effects version, it becomes

$$\delta_{i,j,(1,2)} \sim N\left(d_{t_{ij,(1,2)}} - d_{t_{i1,(1,2)}}, \sigma_{(1,2)}^2\right). \quad (10)$$

- 6 Treatment effect estimates on interval (0,2) can be derived as

$$d_{k,(0,2)} = d_{k,(0,1)} + d_{k,(1,2)}. \quad (11)$$

- 7 In theory, it would be possible for 2-year RCTs to provide data on **only** (0,2) or on (1,2) and
8 (0,2). These could easily be integrated in this model. In practice, there were no such trials in
9 our evidence-base.

G.1.2.10 Weighted mean differences and standardised mean differences

- 11 Differences between continuous treatment effects – in this case, differences in change from
12 baseline to follow-up – can be expressed on the natural scale on which they have been
13 estimated – in this case, ETDRS letters – in the form of a weighted mean difference.

- 14 However, it may also be useful to standardise the contrasts by scaling each by a common
15 standard deviation, so that each RCT provides data on how many SDs difference is
16 observed between treatments. In the case in hand, there was particular value in doing this,
17 as it provided convenient outputs for the health economic analysis.

- 18 Whereas, in a pairwise analysis, it is conventional to scale the pairwise difference by the
19 pooled SD of the 2 observations, this can be extended, in the context of NMA, so that all trial-
20 level contrasts are scaled by a SD pooled across all arms of a trial. So, for each of a arms of
21 trial i at timepoint y , with observed SDs $s_{i,j,y}$, the pooled estimate is

$$s_{i,y} = \sqrt{\frac{\sum_{j=1}^{j=a_i} s_{i,j,y}^2 (n_{i,j,y} - 1)}{\sum_{j=1}^{j=a_i} (n_{i,j,y} - 1)}} \quad (12)$$

- 22 This quantity is then used to scale the linear predictors, so that

$$\theta_{i,j,y} = (\mu_{i,y} + \delta_{i,j,y})s_{i,y}. \quad (13)$$

- 23 Meta-regression terms may be incorporated into the linear predictor to be scaled, as per (4).

G.1.2.24 Imputing missing SDs

- 25 As is common in syntheses of continuous measures of change, a nontrivial proportion of
26 RCTs did not provide a direct estimate of variability.

- 27 Where SEs or confidence intervals were available, these were converted into SDs.

- 1 In 1 case (TREX), a change value and its dispersion was not reported, but estimates of
 2 baseline and follow-up BCVA along with SDs were available. In this circumstance, the mean
 3 change is trivially calculated as $BCVA_{endpoint} - BCVA_{baseline}$; however, in order to estimate the
 4 variance of the change, it is necessary to specify a coefficient representing within-patient
 5 correlation between baseline and follow-up. In the absence of other data, we assumed a
 6 correlation coefficient of 0.5, which is commonly adopted in this circumstance and is
 7 considered conservative (NICE DSU TSD2 [Dias et al., 2012]).
- 8 In cases in which no estimate of dispersion was provided, but categorical counts of people
 9 achieving different levels of gain/loss were available, the missing continuous variance (σ^2) of
 10 arm k of trial j could be approximated by

$$\sigma_{j,k}^2 = \frac{\sum_{i=1}^{i=c_{j,k}} n_{i,j,k} (x_i - MC_{j,k})^2}{\sum_{i=1}^{i=c_{j,k}} n_{i,j,k}}, \quad (14)$$

- 11 , where $c_{j,k}$ is the number of categories reported in the arm, x_i is the average value for the
 12 category in question (mostly defined as the midpoint of the range; see below), $n_{i,j,k}$ is the
 13 number of people achieving that level of change and $MC_{j,k}$ is the reported mean change.

- 14 Where possible, we defined the average value for each category (x_i) as the midpoint of the
 15 range of changes (e.g. -29 to -15 letters = -22 letters). However, this was not possible for
 16 'open-ended' categories (e.g. ≥ 30 letters gained), which exist in all cases. For these, we
 17 assumed that the unknown value for all open intervals was constantly proportional to the
 18 upper (or lower) bound, and used numerical optimisation (Microsoft Excel's solver add-in) to
 19 estimate the optimal value of the multipliers by minimising RMSE across all cases where a
 20 categorically estimated SD could be compared with a true, reported SD. This predicted that
 21 the mean value of 'left-unbounded' intervals was 1.65 times its upper bound (e.g., for ≤ -15 ,
 22 $-15 \times 1.65 = -24.7$) and the mean value of 'right-unbounded' intervals is 1.56 times its lower
 23 bound (e.g., for $\geq +15$, $15 \times 1.56 = 23.5$).

G.1.2.24 Injection frequency

- 25 As a matter of principle, it would have been valuable to adopt the methods set out above to
 26 perform another synthesis of continuous data, to provide a coherent NMA estimating number
 27 of injections required in each regimen. However, data are much more sparsely reported for
 28 this outcome and, even when we imputed as many datapoints as possible, we were unable
 29 to derive an evidence network in which a computationally tractable synthesis could be
 30 performed. For this reason, we were compelled to use a more naïve method when estimating
 31 injection frequency in our health economic model (see appendix J).

G.1.32 Ordered categorical variables

- 33 Another way of reporting change in BCVA is as the proportion of participants experiencing
 34 gains or losses of various magnitudes (e.g. the proportion of people gaining 15 or more
 35 letters). Outcomes such as these can be synthesised as a series of conditional probabilities,
 36 incorporating data on all reported levels of response (network meta-analysis for ordered
 37 categorical data using a generalised linear model with a binomial likelihood and a probit link
 38 function; see NICE DSU TSD2 [Dias et al. 2011a] for technical details).

- 39 Relative effects are estimated as z -scores – standard deviations on a standard normal
 40 distribution – which can then be converted into probabilities. Although we assume, elsewhere
 41 in the analysis undertaken for this guideline, that mean change in BCVA is likely to be
 42 normally distributed, the synthesis model adopted here does not imply any assumption about
 43 the distribution of the underlying variable, despite its use of the standard normal distribution.
 44 The model treats inter-category thresholds as arbitrary and estimates response probabilities
 45 from the response data alone; the actual magnitude of BCVA changes (e.g. 15 letters) is not
 46 an input to the calculation.

1 All categorical data were expressed in consecutive, mutually exclusive categories. This
2 frequently entailed cosmetic manipulation of published data. For example, an RCT might
3 report the proportion of people gaining 15 or more letters, the proportion of people losing 15
4 or more letters, and the proportion of people losing 30 or more letters. Such data were
5 reordered to provide probabilities of change in the following categories:

$$\begin{aligned} & \text{change} \leq -30 \\ -30 & < \text{change} \leq -15 \\ -15 & < \text{change} < +15 \\ +15 & \leq \text{change} \end{aligned}$$

6 Two versions of the analyses were performed. In the **5-category** version, changes were
7 analysed in 15-letter 'bins' that relied on the cut-offs most commonly reported in the included
8 evidence:

$$\begin{aligned} & \text{change} \leq -30 \\ -30 & < \text{change} \leq -15 \\ -15 & < \text{change} < +15 \\ -15 & < \text{change} < +30 \\ +30 & \leq \text{change} \end{aligned}$$

9 In the **10-category** version, changes were analysed in unequally spaced categories that
10 made use of every cut-off reported in at least 1 trial:

$$\begin{aligned} & \text{change} \leq -30 \\ -30 & < \text{change} \leq -15 \\ -15 & < \text{change} \leq -10 \\ -10 & < \text{change} \leq -5 \\ -5 & < \text{change} < 0 \\ 0 & \leq \text{change} < +5 \\ +5 & \leq \text{change} < +10 \\ +10 & \leq \text{change} < +15 \\ +15 & \leq \text{change} < +30 \\ +30 & \leq \text{change} \end{aligned}$$

11 The data were then combined using a model in which the probability (p) of patients in arm j of
12 trial i achieving category k is modelled as

$$p_{ijk} = \Phi(\mu_{i1} + z_k + \delta_{i,j}), \quad (15)$$

13 where Φ represents the cumulative distribution function of the standard normal distribution,
14 μ_{i1} is the trial-specific baseline probability of achieving the first response category with the
15 'control' treatment, z_k represents the differences on the standard normal scale between the
16 response to category k and the response to category $k-1$, and $\delta_{i,j}$ is the trial-specific
17 treatment effect of the treatment in arm j relative to the treatment in arm 1 (defined as per (1)
18 or (2) for fixed- and random-effects models, respectively).

19 In addition to inter-study fixed and random effects, we explored fixed- and random-effects
20 approaches to estimation of the z -score cutpoints. When a random-effects model is adopted,
21 each cutpoint z_k is calculated as the cutpoint for category $k-1$ plus a term representing the
22 difference between the 2 categories, drawn from a lognormal distribution (in order to keep
23 terms positive, as the z -score for a cutpoint cannot be less than the z -score for a category
24 below it).

G.1.45 Dichotomous variables

26 One dichotomous variable – probability of discontinuation – was synthesised. We used a
27 standard model with a binomial likelihood and logit link function (see NICE DSU TSD2 [Dias

1 et al. 2011a]). In this formulation, the log-odds (that is, the logit of the probability, p) of the
2 event occurring in arm j of trial i are estimated as

$$\text{logit}(p_{i,j}) = \mu_i + \delta_{i,j}, \quad (16)$$

3 where $\delta_{i,j}$ is the trial-specific effect of the treatment in arm j relative to the treatment in arm 1
4 (defined as per (1) or (2) for fixed- and random-effects models, respectively). Meta-
5 regression terms may be added to the linear predictor, as per (4).

6 We performed a single analysis, estimating the probability of discontinuation at 1 year (this
7 was used to inform the constant rate of discontinuations incorporated in the health economic
8 model; see appendix J). In theory, it would be attractive to model 1-year and 2-year
9 discontinuations together, with 2-year probabilities formulated as conditional on non-
10 discontinuation in year 1 (see Lu et al. 2007). However, data were somewhat inconsistently
11 reported, in this area, so a simple approach was preferred.

G.2.2 Results

G.2.13 Best-corrected visual acuity


G.2.1.14 Mean change

15 Regardless of model chosen (WMD -v- SMD; discrete nodes -v- meta-regression), the basic
16 network and input data for all mean change syntheses are as shown in Figure 1 and Table 2,
17 respectively.

18 The following features are clear:

- 19 • Ranibizumab 0.5mg monthly is the node with most evidence at both 12 months and
20 24 months, and the option that has been compared with the greatest number of
21 alternatives (this is why it was chosen as the reference option in our NMAs; see G.1.1).
- 22 • There are relatively few data directly comparing PDT with anti-VEGFs (unsurprisingly,
23 given when the various treatments were developed, most PDT evidence is versus sham).
24 Relatedly, there are relatively few data directly comparing anti-VEGF and sham.
- 25 • There are no 2-year data for routine anti-VEGF injection frequencies other than monthly.
26 All 2-year anti-VEGF data relate to routine monthly or PRN regimens (with or without an
27 initial loading phase).
- 28 • Treat-and-extend regimens have only been trialled for bevacizumab and ranibizumab, and
29 there is only 1 small, 1-year RCT in which a treat-and-extend strategy has been directly
30 compared with an alternative regimen using the same agent (ranibizumab). There are no
31 2-year data for this approach.
- 32 • Similarly, PRN-and-extend has only been evaluated in 1 small, 1-year RCT using
33 ranibizumab. There are no 2-year data for this approach.
- 34 • There are no *prima facie* incoherent loops of evidence in the network (e.g. where $a > b$,
35 $b > c$ and $c > a$).

36



1 Figure 1: BCVA: mean change at 12 and 24 months – evidence network

1 Table 2: BCVA: mean change at 12 and 24 months – input data

	Aflib 0.5 1mo	Aflib 0.5 Loading --> PRN <6wkly	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Aflib 2 Loading --> PRN <6wkly	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ran 0.5 1mo	Ran 0.5 Loading --> 3mo	Ran 0.5 Loading --> PRN <6wkly	Ran 0.5 Loading --> PRNX	Ran 0.5 PRN <6wkly	Ran 0.5 Treat and extend	Ran 2 1mo	Ran 2 Loading --> PRN <6wkly	Sham anti-VEGF	Sham PDT	
12 months																								
NATTB 2013								12.58 (13.88)	10.06 (16.00)															
ANCHOR 2006														-9.50 (16.00)	9.90 (14.60)									
Barikian 2015										8.00 (10.40)	8.30 (6.70)													
BISWAS 2011										0.52 (15.63)							3.22 (12.01)							
BRAMD 2016 (naïve)						6.06 (13.67)								6.82 (12.63)										
CATT 2011						8.00 (15.80)					5.90 (15.70)			8.50 (14.10)					6.80 (13.10)					
El-Mollayess						11.00 (10.46)					9.20 (14.72)													
EXCITE 2010														8.00 (11.27)	3.41 (14.35)									
GEFAL 2013										4.82 (14.85)							2.93 (15.09)							
HARBOR														10.10 (13.30)		8.20 (13.30)				9.20 (14.60)	8.60 (13.80)			
IVAN 2013						4.40 (13.20)				5.10 (11.40)				7.80 (14.20)		5.10 (10.40)								
LUCAS 2015												7.90 (13.40)								8.20 (12.50)				
Lushchik 2013						1.90 (13.80)	6.00 (8.90)	1.60 (11.00)																
MANTA 2013										4.90 (15.20)						4.10 (15.31)								

Macular degeneration
Network meta-analysis

	Aflib 0.5 1mo	Aflib 0.5 Loading --> PRN <6wkly	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Aflib 2 Loading --> PRN <6wkly	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ranij 0.5 1mo	Ranij 0.5 Loading --> 3mo	Ranij 0.5 Loading --> PRN <6wkly	Ranij 0.5 Loading --> PRNX	Ranij 0.5 PRN <6wkly	Ranij 0.5 Treat and extend	Ranij 2 1mo	Ranij 2 Loading --> PRN <6wkly	Sham anti-VEGF	Sham PDT	
MARINA														6.85 (13.59)									-10.40 (16.97)	
PIER															-0.89 (14.12)								-16.30 (22.30)	
Sacu 2009									8.00 (11.22)				-3.00 (15.53)											
SALUTE 2015																3.20 (20.90)	7.70 (15.90)							
Subramanian 2010										7.60 (15.38)						6.29 (13.74)								
TREX 2015														9.20 (16.21)					10.50 (10.73)					
VIEW 1&2 POOLED	8.29 (13.75)		9.24 (13.21)	8.40 (14.70)										8.74 (14.45)										
VIO													-11.20 (18.75)											-13.30 (15.34)
TAP 1999													-11.00 (20.19)											-17.50 (20.75)
VIM 2005													-8.50 (16.06)											-14.50 (18.13)
VIP 2001 Occ only													-15.60 (20.77)											-20.80 (22.45)
24 months																								
ANCHOR 2006													-9.80 (17.60)	9.40 (16.35)										
CATT 2011						7.80 (15.50)					5.00 (17.90)			8.80 (15.90)				6.70 (14.60)						
HARBOR														9.10 (14.90)		7.90 (14.70)				8.00 (17.40)	7.60 (15.30)			
IVAN 2013						3.60 (15.20)								7.30 (15.20)		2.60 (14.40)								

Macular degeneration
Network meta-analysis

	Aflib 0.5 1mo	Aflib 0.5 Loading --> PRN <6wkly	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Aflib 2 Loading --> PRN <6wkly	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ranij 0.5 1mo	Ranij 0.5 Loading --> 3mo	Ranij 0.5 Loading --> PRN <6wkly	Ranij 0.5 Loading --> PRNX	Ranij 0.5 PRN <6wkly	Ranij 0.5 Treat and extend	Ranij 2 1mo	Ranij 2 Loading --> PRN <6wkly	Sham anti-VEGF	Sham PDT	
MARINA														6.00 (15.13)									-14.90 (18.90)	
VIEW 1&2 POOLED		6.59 (15.21)			7.62 (15.81)											7.89 (16.11)								
VIO													-14.80 (20.30)											-17.78 (16.71)
TAP 1999													-13.40 (21.79)											-19.60 (21.86)
VIM 2005													-16.00 (20.01)											-21.00 (22.50)
VIP 2001 Occ only													-19.00 (22.57)											-25.50 (22.55)

Values are mean change from baseline to follow up (SD). Where individual trials have more than 1 arm representing a treatment option, they have been pooled in this table for ease of interpretation, although they are entered as separate datapoints in the NMA.


1 **G.2.1.1.1 Mean difference at 12 and 24 months (bivariate normal likelihood)**

2 **G.2.1.1.1.1 Model selection**

3 A wide variety of models was explored for this outcome, as it provided the most complete
4 summary of available effectiveness data, and it was critical for the parameterisation of the
5 health economic model.

6 The first choice we made was to separate ‘sham anti-VEGF’ and ‘sham-PDT’ nodes in the
7 networks. This was because preliminary exploration showed that there was inconsistency
8 associated with RCTs of PDT -v- sham, when ‘sham’ was treated as a single node (see
9 Figure 2A). This problem was resolved when the node was separated into its 2 component
10 elements (see Figure 2B), and measure of model fit, including DIC and residual deviance
11 (not shown), were also improved. Therefore, we concluded this was a superior approach,
12 and treated ‘sham anti-VEGF’ and ‘sham-PDT’ as separate entities.

13



14 **Figure 2: Comparison of residual deviance between full NMA and inconsistency**
15 **model, when sham anti-VEGF and sham PDT are treated as (A) a single node**
16 **or (B) separate nodes**

17 This gave us a network with up to 23 agent–dose–regimen triads. To help illustrate the
18 features of the evidence network, we provide outputs of a ‘split’ NMA (that is, one with a
19 discrete node for every agent–dose–regimen triad, amounting to 23 nodes) on the natural
20 (mean difference in ETDRS letters) scale in G.2.1.1.2.

21 Summary fit statistics for each model are given in Table 3. Some features are immediately
22 obvious: fixed-effects models always have higher residual deviance than their random-effects
23 counterparts and adjusted (meta-regression) models have meaningfully superior DIC to their
24 ‘split’, 23-node equivalents.

25 Therefore, there is strong justification for preferring a meta-regression model that, at a
26 minimum, treats the effect of PRN administration as shared among all anti-VEGF agents.
27 The value that is added by distinguishing between PRN regimens with and without loading
28 phases is less apparent. DIC goes up somewhat and other measures of model fit are no
29 better when the term is included. This is in keeping with the pairwise evidence showing that

1 no difference between these approaches could be identified at 1 year (see full guideline
2 10.1.4.3.1). Nevertheless, we opted to retain this term in the model, as it was perceived to
3 have potentially important consequences for the health economic analysis: if the term was
4 dropped, we would have been forced either to model an average of loading and non-loading
5 approaches (which it would not be straightforward to cost) or to state from the outset that
6 pre-PRN loading has no value, and assume that such costs should never be incurred (this is
7 also at odds with the SPC for ranibizumab).

8 Treating TREX and PRNX as shared covariates results in a very small improvement in model
9 fit. As including these terms certainly did not harm the synthesis model, and it enabled the
10 strategies to be entered into the health economic model in a flexible way (including the
11 speculative exploration of PRNX and TREX regimens for agents in which they have not been
12 empirically researched), we concluded they should be retained.

13 The most complicated decision was as regards how frequency of administration could best
14 be represented. All 3 models that were explored showed slightly inferior DIC to models in
15 which separate routine frequencies were treated as separate nodes. However, this requires
16 close exploration.

17 In particular, we noted that a single datapoint was having a large influence on the frequency-
18 adjusted models. It can be seen, in G.2.1.1.2 (most clearly shown in Figure 9), that the
19 estimate for bevacizumab given at 2-monthly intervals presents an unexpectedly positive
20 result. Elsewhere in that network, the expected frequency–response relationship is seen; for
21 example, 6-weekly bevacizumab is slightly worse than monthly, and 3-monthly bevacizumab
22 is worse again. However, the point-estimate for bevacizumab 2-monthly is that it is better
23 than monthly treatment, and has a relatively high chance (>0.3) of being the most effective
24 strategy in the split WMD network. We note that this finding is entirely consistent with
25 expected levels of simple random sampling error – note that the credible intervals are wide
26 and overlap in a way that makes the expected frequency–response relationship entirely
27 plausible, at a 95% confidence level. On inspection of input data (see Table 2), it can be
28 seen that this finding results from a single RCT (Lushchik et al., 2013), in which the 2-
29 monthly bevacizumab group (n=54) gained 6 ETDRS letters at 1 year, whereas the 1-
30 monthly bevacizumab group (n=46) gained a little under 2 (a similar finding is evident in the
31 categorical data – see Table 28). Again, we emphasise that there is no reason to believe this
32 is a fundamentally biased finding – it is within the range of expected sampling error if there
33 were no difference between the strategies (i.e. it is not a ‘significant’ difference).
34 Nevertheless, it is one that would, on average, be propagated throughout the evidence if
35 taken on face value. For example, if the split network were used as a basis for health
36 economic analysis, 2-monthly bevacizumab would be sure to have a high probability of being
37 optimal – it would be prominent in CEACs – even though the uncertainty attached to the
38 estimate would also result in it having a (largely unseen) non-negligible probability of being a
39 poor choice.

40 This kind of finding is a strong motivation for adopting a frequency–response model that
41 seeks to establish what the average relationship between frequency and effect is throughout
42 the network, and then combines that with what is known about monthly administration to
43 arrive at an estimate that makes best use of all available data.

44 To explore this, we performed a series of sensitivity analyses in which the models were
45 refitted to a dataset that excluded the single anomalous datapoint from Lushchik et al.
46 (2013). When we did this, we found that all frequency-adjusted models had a superior fit to
47 the data, with DIC dropping by up to 5 points, compared with unadjusted models.

48 Therefore, we concluded that a frequency–response model provided the optimal
49 representation of the evidence, and preferred this approach for our selected model for the full
50 dataset. In this context, the fact that frequency-adjusted models have a slightly worse fit to
51 the observed data is actually a desirable property, as the datapoint that they fit poorly is the

1 one that was inconsistent with other data, showing that the approach has been effective in
2 minimising the influence of the outlying estimate.

3 It was hard to distinguish between the 3 frequency–response models, and a good argument
4 could be made for adopting the simplest – MR4a – which assumes that a single frequency–
5 response effect is shared between all anti-VEGFs. However, the committee advised that
6 most clinicians would have an a priori assumption that there would at least be a difference
7 between aflibercept and the 2 monoclonal antibodies, with aflibercept providing slightly
8 longer-lasting benefits. Therefore, we concluded it would be conservative to distinguish
9 between these options, and model MR4c – which had very marginally better fit to the data
10 that MR4b in the sensitivity analysis excluding the anomalous datapoint from Lushchik et al.
11 (2013) – was preferred.

12 In relection of all the above considerations, our final preferred choice for the 12- and 24-
13 month mean difference synthesis was the **random-effects** model adjusting for **PRN**, pre-
14 **PRN loading**, **TREX**, **PRNX** and **frequency** (with separate terms for aflibercept and
15 monoclonal antibodies).

16 Although residual deviance was higher with fixed-effects models, they tended to be
17 associated with DIC values that were at least equivalent to random-effects counterparts. This
18 was particularly true for meta-regression approaches: fixed-effects models fitted the split data
19 less well; however, introducing covariates explained a good deal of the heterogeneity.
20 Because a case could be made for preferring the fixed-effects models, we captured the
21 results from FIXED MR4c, and used it in a sensitivity analysis for our HE model.

22 **Table 3: BCVA: mean difference at 12 and 24 months – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	Between-study SD
91.77 (compared to 92 datapoints)	265.3	199.6	65.74	331.1	12 months: 0.71 (95%CrI: 0.03, 1.96) 24 months: 0.48 (95%CI: 0.03, 1.33)

23

1 Table 4: BCVA: mean difference at 12 and 24 months – summary model fit statistics, showing selection of best-fitting model

Outcome	Model for treatment differences	Number of discrete nodes	Covariates					N	Total residual deviance	DIC	Standard deviation of random effects distributions (95%CrI)	
			PRN	Loading	TREX	PRNX	Frequency				0–12 months	12–24 months
Mean change in BCVA at 12 & 24 months	FIXED	23						97.19	335.8	n/a	n/a	
	FIXED MR1	16	✓					88.05	320.8	n/a	n/a	
	FIXED MR2	16	✓	✓				89.23	323.7	n/a	n/a	
	FIXED MR3	13	✓	✓	✓	✓		88.12	321.5	n/a	n/a	
	FIXED MR4a	8	✓	✓	✓	✓	✓	98.89	328.4	n/a	n/a	
	FIXED MR4b	8	✓	✓	✓	✓	✓	97.29	328.9	n/a	n/a	
	FIXED MR4c	8	✓	✓	✓	✓	✓	99.40	330.0	n/a	n/a	
	RANDOM	23						87.66	334.6	0.55 (0.02, 1.91)	0.69 (0.08, 1.90)	
	RANDOM MR1	16	✓					86.45	325.5	0.47 (0.02, 1.56)	0.47 (0.04, 1.25)	
	RANDOM MR2	16	✓	✓				87.89	329.3	0.51 (0.01, 1.69)	0.48 (0.03, 1.35)	
	RANDOM MR3	13	✓	✓	✓	✓		86.90	327.2	0.49 (0.02, 1.59)	0.50 (0.04, 1.36)	
	RANDOM MR4a	8	✓	✓	✓	✓	✓	91.82	329.8	0.61 (0.04, 1.83)	0.48 (0.03, 1.29)	
	RANDOM MR4b	8	✓	✓	✓	✓	✓	90.78	329.9	0.58 (0.04, 1.77)	0.49 (0.03, 1.32)	
	RANDOM MR4c	8	✓	✓	✓	✓	✓	91.77	331.1	0.71 (0.03, 1.96)	0.48 (0.03, 1.33)	
	Mean change in BCVA at 12 & 24 months (sensitivity analysis excluding Bev 2mo from Lushchik 2013)	FIXED	22						103.90	324.3	n/a	n/a
		FIXED MR1	15	✓					86.80	316.0	n/a	n/a
FIXED MR2		15	✓	✓				88.29	319.6	n/a	n/a	
FIXED MR3		12	✓	✓	✓	✓		87.14	317.3	n/a	n/a	
FIXED MR4a		8	✓	✓	✓	✓	✓	89.23	316.5	n/a	n/a	
FIXED MR4b		8	✓	✓	✓	✓	✓	89.91	319.3	n/a	n/a	
FIXED MR4c		8	✓	✓	✓	✓	✓	88.95	317.3	n/a	n/a	
RANDOM		22						89.90	322.9	1.04 (0.10, 2.14)	0.42 (0.03, 1.13)	
RANDOM MR1		15	✓					85.96	322.3	0.46 (0.02, 1.56)	0.47 (0.03, 1.29)	
RANDOM MR2		15	✓	✓				86.89	325.1	0.52 (0.01, 1.69)	0.48 (0.04, 1.34)	
RANDOM MR3		12	✓	✓	✓	✓		85.90	322.6	0.46 (0.02, 1.53)	0.48 (0.02, 1.32)	
RANDOM MR4a		8	✓	✓	✓	✓	✓	84.32	318.3	0.42 (0.02, 1.40)	0.49 (0.04, 1.34)	
RANDOM MR4b		8	✓	✓	✓	✓	✓	85.16	320.9	0.43 (0.02, 1.49)	0.48 (0.02, 1.36)	
RANDOM MR4c		8	✓	✓	✓	✓	✓	84.55	319.3	0.41 (0.02, 1.38)	0.50 (0.03, 1.34)	

MR4a = 1 covariate shared between anti-VEGF agents for frequency–response effect; MR4b = separate covariates for each anti-VEGF agent for frequency–response effect; MR4c = 1 covariate for aflibercept and 1 covariate for bevacizumab and ranibizumab for frequency–response effect;

1 G.2.1.1.1.2 12 months

2 Table 5: BCVA: mean difference at 12 months – relative effectiveness of all pairwise combinations


Sham																						
17.1 (13.4, 20.8)	Aflib 0.5																					
18.9 (13.8, 23.9)	1.8 (-2.5, 6.0)	Aflib 2																				
18.6 (15.2, 21.9)	1.6 (-1.5, 4.5)	-0.2 (-5.0, 4.3)	Beva 1.25																			
-1.2 (-5.4, 3.2)	-18.2 (-22.4, -14.0)	-20.1 (-25.4, -14.5)	-19.8 (-23.4, -16.0)	PDT																		
19.0 (15.8, 22.2)	2.0 (-0.9, 4.7)	0.2 (-4.4, 4.6)	0.4 (-0.8, 1.6)	20.2 (16.5, 23.7)	Rani 0.5																	
17.3 (13.8, 20.8)	0.2 (-3.2, 3.5)	-1.6 (-6.4, 3.2)	-1.4 (-4.0, 1.4)	18.5 (14.4, 22.3)	-1.8 (-4.2, 0.7)	Rani 2																
-5.9 (-10.7, -0.9)	-23.0 (-27.6, -18.1)	-24.8 (-30.5, -18.7)	-24.5 (-28.8, -19.9)	-4.7 (-9.3, 0.2)	-24.9 (-29.0, -20.5)	-23.1 (-27.7, -18.5)	Sham PDT															
17.4 (12.1, 22.7)	0.3 (-4.3, 5.0)	-1.5 (-3.1, 0.2)	-1.2 (-6.1, 3.9)	18.6 (12.9, 24.2)	-1.6 (-6.3, 3.2)	0.1 (-5.0, 5.3)	23.3 (17.1, 29.4)	Aflib 2 PRN														
17.2 (13.4, 20.8)	0.1 (-3.4, 3.4)	-1.7 (-6.6, 3.0)	-1.5 (-3.1, 0.2)	18.3 (14.2, 22.3)	-1.9 (-3.8, 0.0)	-0.1 (-3.2, 3.0)	23.0 (18.3, 27.6)	-0.2 (-5.0, 4.3)	Beva 1.25 PRN													
17.6 (13.9, 21.1)	0.5 (-2.8, 3.7)	-1.3 (-6.1, 3.4)	-1.1 (-3.2, 1.1)	18.7 (14.7, 22.6)	-1.5 (-3.1, 0.2)	0.3 (-2.7, 3.2)	23.4 (18.7, 27.9)	0.2 (-4.4, 4.6)	0.4 (-0.8, 1.6)	Rani 0.5 PRN												
17.6 (12.3, 22.8)	0.5 (-4.1, 4.9)	-1.3 (-2.8, 0.1)	-1.1 (-5.8, 3.8)	18.8 (13.1, 24.2)	-1.5 (-6.1, 3.3)	0.3 (-4.8, 5.3)	23.5 (17.3, 29.3)	0.2 (-2.0, 2.2)	0.4 (-4.6, 5.5)	0.0 (-4.9, 4.9)	Aflib 2 PRNL											
17.3 (13.6, 20.9)	0.3 (-3.2, 3.5)	-1.5 (-6.5, 3.2)	-1.3 (-2.8, 0.1)	18.5 (14.5, 22.4)	-1.7 (-3.6, 0.1)	0.1 (-3.1, 3.1)	23.2 (18.5, 27.7)	-0.1 (-5.3, 4.9)	0.2 (-2.0, 2.2)	-0.2 (-2.8, 2.3)	-0.2 (-5.0, 4.3)	Beva 1.25 PRNL										
17.7 (14.2, 21.2)	0.7 (-2.6, 3.8)	-1.1 (-5.9, 3.5)	-0.9 (-2.8, 1.0)	18.9 (14.9, 22.6)	-1.3 (-2.8, 0.1)	0.4 (-2.5, 3.3)	23.6 (18.9, 28.0)	0.3 (-4.7, 5.2)	0.6 (-1.7, 2.8)	0.2 (-2.0, 2.2)	0.2 (-4.4, 4.6)	0.4 (-0.8, 1.6)	Rani 0.5 PRNL									

Macular degeneration

Network meta-analysis


Table with 25 columns and 20 rows. Each row contains numerical data representing mean differences and 95% credible intervals for various treatments. The diagonal elements are highlighted in green and labeled with treatment names and durations (e.g., Aflib 2, Beva 1.25, Rani 0.5, etc.).

Values given are mean differences in ETDRS letters (row versus column; i.e. negative numbers favour the option above and positive numbers favour the option on the right). Data are derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects. The point estimate reflects the mean of the posterior distribution, and numbers in parentheses are 95% credible intervals.



1 **Figure 3: BCVA: mean difference at 12 months – relative effect of all options versus**
 2 **sham anti-VEGF**

3



4 **Figure 4: BCVA: mean difference at 12 months – expected absolute change**

1 **Table 6: BCVA: mean difference at 12 months – meta-regression coefficients**


Covariate		Beta	(95%CrI)
PRN		-1.46	(-3.12, 0.23)
Loading		0.16	(-1.99, 2.24)
TREX		1.28	(-6.74, 9.25)
PRNX		4.43	(-3.98, 12.75)
Frequency (per additional month)	Aflibercept	-0.84	(-3.32, 1.64)
	Bevacizumab / ranibizumab	-1.49	(-2.75, -0.19)

Values on natural scale (ETDRS letters); negative values indicate worse BCVA

2 **Table 7: BCVA: mean difference at 12 months – rankings for each comparator**

	Probability best	Median rank (95%CI)
Sham	0.000	24 (24, 25)
Aflib 0.5	0.003	16 (5, 23)
Aflib 2	0.035	7 (1, 20)
Beva 1.25	0.012	8 (2, 16)
PDT	0.000	25 (24, 25)
Rani 0.5	0.029	7 (1, 13)
Rani 2	0.004	15 (4, 23)
ShamPDT	0.000	26 (26, 26)
Aflib 2; PRN	0.002	14 (3, 23)
Beva 1.25; PRN	0.001	16 (6, 23)
Rani 0.5; PRN	0.002	13 (5, 22)
Aflib 2; PRN+Load	0.001	14 (4, 23)
Beva 1.25; PRN+Load	0.000	15 (6, 23)
Rani 0.5; PRN+Load	0.001	12 (5, 21)
Aflib 2; TREX	0.151	5 (1, 23)
Beva 1.25; TREX	0.047	6 (1, 23)
Rani 0.5; TREX	0.133	5 (1, 22)
Aflib 2; PRNX	0.259	3 (1, 23)
Beva 1.25; PRNX	0.085	3 (1, 23)
Rani 0.5; PRNX	0.230	3 (1, 22)
Aflib 2; 2mo	0.000	11 (4, 19)
Beva 1.25; 2mo	0.000	16 (8, 21)
Rani 0.5; 2mo	0.000	13 (6, 19)
Aflib 2; 3mo	0.005	15 (4, 23)
Beva 1.25; 3mo	0.000	22 (12, 23)
Sham	0.000	24 (24, 25)

3



1 Figure 5: BCVA: mean difference at 12 months – rank probability histograms


2

1 G.2.1.1.1.3 24 months

2 Table 8: BCVA: mean difference at 24 months – relative effectiveness of all pairwise combinations


Sham																					
19.9 (15.6, 24.2)	Aflib 0.5																				
22.2 (16.7, 27.6)	2.3 (-2.2, 6.7)	Aflib 2																			
22.2 (18.3, 26.1)	2.3 (-1.3, 5.8)	0.0 (-5.0, 4.9)	Beva 1.25																		
2.6 (-2.2, 7.7)	-17.2 (-21.9, -12.3)	-19.5 (-25.3, -13.6)	-19.5 (-23.7, -15.1)	PDT																	
22.7 (19.1, 26.2)	2.8 (-0.5, 5.9)	0.5 (-4.2, 5.1)	0.5 (-1.1, 2.1)	20.0 (15.8, 23.9)	Rani 0.5																
20.5 (16.5, 24.5)	0.6 (-3.3, 4.5)	-1.7 (-6.8, 3.4)	-1.7 (-4.8, 1.5)	17.8 (13.3, 22.2)	-2.2 (-4.9, 0.6)	Rani 2															
-2.6 (-8.1, 3.1)	-22.4 (-27.8, -16.9)	-24.8 (-31.0, -18.2)	-24.8 (-29.6, -19.6)	-5.2 (-7.9, -2.6)	-25.2 (-29.9, -20.3)	-23.0 (-28.1, -17.8)	Sham PDT														
20.3 (14.2, 26.3)	0.4 (-4.7, 5.5)	-1.9 (-4.4, 0.6)	-1.9 (-7.4, 3.7)	17.6 (11.2, 23.9)	-2.4 (-7.6, 2.9)	-0.2 (-5.8, 5.5)	22.8 (15.9, 29.6)	Aflib 2 PRN													
20.3 (15.6, 24.9)	0.4 (-3.9, 4.7)	-1.9 (-7.4, 3.5)	-1.9 (-4.4, 0.6)	17.6 (12.6, 22.4)	-2.4 (-5.3, 0.5)	-0.2 (-4.2, 3.8)	22.8 (17.2, 28.2)	0.0 (-5.0, 4.9)	Beva 1.25 PRN												
20.8 (16.4, 25.1)	0.9 (-3.2, 4.9)	-1.4 (-6.7, 3.7)	-1.4 (-4.4, 1.5)	18.1 (13.3, 22.7)	-1.9 (-4.4, 0.6)	0.3 (-3.4, 3.9)	23.3 (17.8, 28.6)	0.5 (-4.2, 5.1)	0.5 (-1.1, 2.1)	Rani 0.5 PRN											
21.1 (15.2, 26.7)	1.2 (-3.7, 5.9)	-1.2 (-2.9, 0.5)	-1.2 (-6.4, 4.1)	18.4 (12.2, 24.3)	-1.6 (-6.6, 3.3)	0.6 (-4.9, 5.9)	23.6 (16.8, 30.1)	0.7 (-2.2, 3.7)	0.7 (-5.0, 6.5)	0.3 (-5.2, 5.8)	Aflib 2 PRN+Load										
21.0 (16.8, 25.3)	1.2 (-2.8, 5.0)	-1.1 (-6.5, 3.9)	-1.2 (-2.9, 0.5)	18.4 (13.7, 22.8)	-1.6 (-3.9, 0.6)	0.6 (-3.1, 4.1)	23.6 (18.2, 28.7)	0.8 (-5.1, 6.4)	0.7 (-2.2, 3.7)	0.3 (-3.1, 3.6)	0.0 (-5.0, 4.9)	Beva 1.25 PRN+Load									

Values given are mean differences (negative numbers favour the option above; positive numbers favour the option on the right)
Data are derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects. The point estimate reflects the mean of the posterior distribution, and numbers in parentheses are 95% credible intervals.



1 **Figure 6: BCVA: mean difference at 24 months – relative effect of all options versus**
2 **sham anti-VEGF**

3



4 **Figure 7: BCVA: mean difference at 24 months – expected absolute change**

1 **Table 9: BCVA: mean difference at 12 months – meta-regression coefficients**


Covariate	Beta	(95%CrI)
PRN	-1.91	(-4.36, 0.57)
Loading	0.74	(-2.25, 3.66)

Values on natural scale (ETDRS letters); negative values indicate worse BCVA

2 **Table 10: BCVA: mean difference at 24 months – rankings for each comparator**

	Probability best	Median rank (95%CI)
Sham	0.000	13 (12, 14)
Aflib 0.5	0.012	9 (3, 11)
Aflib 2	0.322	3 (1, 9)
Beva 1.25	0.159	3 (1, 8)
PDT	0.000	12 (12, 13)
Rani 0.5	0.342	2 (1, 6)
Rani 2	0.026	8 (1, 11)
ShamPDT	0.000	14 (13, 14)
Aflib 2; PRN	0.023	8 (2, 11)
Beva 1.25; PRN	0.010	8 (2, 11)
Rani 0.5; PRN	0.025	7 (2, 11)
Aflib 2; PRN+Load	0.034	6 (1, 11)
Beva 1.25; PRN+Load	0.012	6 (2, 11)
Rani 0.5; PRN+Load	0.036	5 (1, 10)

3



1 **Figure 8: BCVA: mean difference at 24 months – rank probability histograms**

2 **G.2.1.1.2 Mean difference at 12 and 24 months (bivariate normal likelihood) – split**
3 **network**

4 **Table 11: BCVA: mean difference at 12 and 24 months – model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	Between-study SD
87.75 (compared to 93 datapoints)	261.3	187.7	73.62	334.9	0–12 months: 0.574 (95%CI: 0.031, 1.887) 12–24 months: 0.701 (95%CI: 0.079, 1.918)

5

1 G.2.1.1.2.1 12 months

2 Table 12: BCVA: mean difference at 12 months – relative effectiveness of all pairwise combinations


3

	Ranij0.5 1mo	Afibj0.5 1mo	Afibj0.5 Loading --> PRN <6wkly	Afibj2 1mo	Afibj2 Loading --> 2mo	Afibj2 Loading --> PRN <6wkly	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ranij0.5 Loading --> 3mo	Ranij0.5 Loading --> PRN <6wkly	Ranij0.5 Loading --> PRNX	Ranij0.5 PRN <6wkly	Ranij0.5 Treat and extend	Ranij2 1mo	Ranij2 Loading --> PRN <6wkly	Sham anti-VEGF	Sham PDT
Ranij0.5 1mo		-0.4 (-2.0, 1.2)	-	0.5 (-1.1, 2.1)	-0.3 (-2.0, 1.3)	-	-1.6 (-3.0, -0.2)	-	-	-	-2.7 (-5.0, -0.5)	-3.0 (-5.0, -1.0)	-	-19.3 (-21.6, -17.0)	-4.6 (-7.3, -1.8)	-2.3 (-3.6, -0.9)	-	-1.8 (-3.7, 0.0)	1.3 (-6.5, 9.1)	-1.0 (-2.8, 0.8)	-1.5 (-3.2, 0.2)	-19.0 (-22.6, -15.4)	-
Afibj0.5 1mo	-0.4 (-2.8, 2.0)		-	0.9 (-0.6, 2.5)	0.1 (-1.5, 1.7)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Afibj0.5 Loading --> PRN <6wkly	-	-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Afibj2 1mo	0.5 (-1.9, 2.8)	1.0 (-1.3, 3.2)	-		-0.8 (-2.4, 0.7)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Afibj2 Loading --> 2mo	-0.3 (-2.7, 2.1)	0.1 (-2.3, 2.4)	-	-0.8 (-3.3, 1.5)		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Afibj2 Loading --> PRN <6wkly	-	-	-	-	-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Beva 1.25 1mo	-1.4 (-3.3, 0.4)	-0.9 (-4.1, 2.0)	-	-1.9 (-5.0, 1.0)	-1.1 (-4.2, 2.0)	-		4.1 (-0.5, 8.7)	-0.3 (-5.2, 4.6)	-	0.8 (-1.4, 3.0)	-2.3 (-4.2, -0.3)	-	-	-	0.1 (-2.2, 2.3)	-	-1.2 (-3.1, 0.8)	-	-	-	-	-
Beva 1.25 2mo	2.6 (-2.7, 7.8)	3.0 (-2.7, 8.8)	-	2.1 (-3.7, 7.8)	2.9 (-2.9, 8.8)	-	3.9 (-0.9, 8.8)		-4.4 (-8.1, -0.7)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Beva 1.25 6wk	-2.0 (-7.2, 3.5)	-1.4 (-7.3, 4.5)	-	-2.4 (-8.2, 3.5)	-1.6 (-7.4, 4.4)	-	-0.5 (-5.5, 4.6)	-4.4 (-8.6, -0.4)		-2.5 (-7.1, 2.1)	-	-	-	-	-	-	-	-	-	-	-	-	-
Beva 1.25 Loading --> 12wk	-4.5 (-11.8, 2.8)	-4.0 (-11.7, 3.6)	-	-5.0 (-12.7, 2.8)	-4.2 (-11.7, 3.6)	-	-3.1 (-10.2, 4.0)	-2.6 (-7.4, 2.3)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Beva 1.25 Loading --> PRN <6wkly	-1.9 (-4.2, 0.2)	-1.5 (-4.8, 1.6)	-	-2.4 (-5.7, 0.7)	-1.6 (-4.9, 1.6)	-	-0.5 (-2.9, 1.8)	-4.4 (-10.0, 0.9)	0.0 (-5.6, 5.5)	2.5 (-4.9, 10.2)		0.3 (-4.1, 4.7)	-	-11.0 (-21.0, -1.0)	-	-0.8 (-2.2, 0.7)	-	-	-	-	-	-	-

Macular degeneration
Network meta-analysis


	Ranij0.5 1mo	Aflib0.5 1mo	Aflib0.5 Loading --> PRN <6wkly	Aflib2 1mo	Aflib2 Loading --> 2mo	Aflib2 Loading --> PRN <6wkly	Bevaj1.25 1mo	Bevaj1.25 2mo	Bevaj1.25 6wk	Bevaj1.25 Loading --> 12wk	Bevaj1.25 Loading --> PRN <6wkly	Bevaj1.25 PRN <6wkly	Bevaj1.25 Treat and extend	PDT PRN >6wkly	Ranij0.5 Loading --> 3mo	Ranij0.5 Loading --> PRN <6wkly	Ranij0.5 Loading --> PRNX	Ranij0.5 PRN <6wkly	Ranij0.5 Treat and extend	Ranij2 1mo	Ranij2 Loading --> PRN <6wkly	Sham anti-VEGF	Sham PDT	
Bevaj1.25 PRN <6wkly	-2.8 (-5.2, -0.4)	-2.4 (-5.7, 1.0)	-	-3.3 (-6.6, 0.1)	-2.5 (-5.8, 0.9)	-	-1.4 (-3.7, 1.0)	-5.3 (-10.9, -0.1)	-0.9 (-6.4, 4.6)	1.7 (-5.8, 9.1)	-0.8 (-3.5, 1.8)		-	-	-	-	-	1.2 (-0.6, 3.1)	-	-	-	-	-	
Bevaj1.25 Treat and extend	1.1 (-7.7, 9.2)	1.5 (-7.7, 10.1)	-	0.5 (-8.6, 9.0)	1.4 (-7.7, 9.8)	-	2.4 (-6.5, 10.9)	-1.6 (-12.0, 8.2)	2.9 (-7.8, 12.7)	5.5 (-6.1, 16.9)	3.0 (-5.9, 11.5)	3.8 (-5.3, 12.3)		-	-	-	-	-	0.3 (-2.3, 2.9)	-	-	-	-	
PDT PRN >6wkly	-18.7 (-22.0, -15.4)	-18.2 (-22.3, -14.1)	-	-19.2 (-23.2, -15.1)	-18.4 (-22.5, -14.2)	-	-17.2 (-21.0, -13.4)	-21.2 (-27.6, -15.1)	-16.8 (-23.2, -10.5)	-14.3 (-22.2, -6.0)	-16.7 (-20.7, -13.0)	-15.8 (-20.0, -11.9)	-19.7 (-28.8, -10.6)		-	-	-	-	-	-	-	-	-4.8 (-6.4, -3.2)	
Ranij0.5 Loading -> 3mo	-4.1 (-6.9, -1.3)	-3.7 (-7.4, 0.0)	-	-4.7 (-8.2, -0.9)	-3.8 (-7.5, -0.1)	-	-2.7 (-6.0, 0.7)	-6.6 (-12.6, -0.9)	-2.2 (-8.4, 3.9)	0.3 (-7.5, 8.2)	-2.2 (-5.7, 1.5)	-1.4 (-5.1, 2.4)	-5.2 (-13.6, 3.9)	14.5 (10.2, 19.0)		-	-	-	-	-	-	-	-15.4 (-21.5, -9.4)	-
Ranij0.5 Loading -> PRN <6wkly	-2.1 (-4.1, -0.2)	-1.7 (-4.8, 1.3)	-	-2.7 (-5.7, 0.3)	-1.8 (-5.0, 1.1)	-	-0.8 (-3.0, 1.5)	-4.7 (-10.1, 0.5)	-0.3 (-5.9, 5.3)	2.2 (-5.0, 10.0)	-0.2 (-2.0, 1.5)	0.6 (-2.1, 3.3)	-3.2 (-11.6, 5.7)	16.5 (12.8, 20.3)	2.0 (-1.5, 5.3)		4.5 (-3.8, 12.8)	-	-	0.6 (-1.2, 2.4)	0.1 (-1.6, 1.8)	-	-	
Ranij0.5 Loading -> PRNX	2.1 (-6.4, 10.7)	2.5 (-6.3, 11.5)	-	1.6 (-7.3, 10.7)	2.4 (-6.3, 11.4)	-	3.5 (-5.1, 12.3)	-0.5 (-10.6, 9.9)	4.0 (-6.3, 14.4)	6.6 (-4.8, 18.5)	4.0 (-4.5, 12.6)	4.9 (-3.9, 13.7)	0.9 (-10.7, 13.4)	20.8 (11.6, 30.0)	6.2 (-2.7, 15.2)	4.3 (-4.1, 12.7)		-	-	-	-	-	-	
Ranij0.5 PRN <6wkly	-2.0 (-4.6, 0.5)	-1.5 (-5.1, 1.9)	-	-2.5 (-6.1, 0.9)	-1.7 (-5.3, 1.8)	-	-0.6 (-3.2, 2.0)	-4.6 (-10.1, 0.8)	-0.1 (-5.8, 5.5)	2.4 (-5.1, 10.1)	-0.1 (-3.2, 3.0)	0.8 (-2.0, 3.5)	-3.1 (-11.7, 6.1)	16.6 (12.5, 20.8)	2.1 (-1.8, 5.9)	0.2 (-2.8, 3.1)	-4.1 (-13.0, 4.8)		-	-	-	-	-	
Ranij0.5 Treat and extend	1.3 (-6.6, 9.1)	1.8 (-6.8, 10.0)	-	0.8 (-7.6, 8.9)	1.6 (-6.8, 9.9)	-	2.7 (-5.6, 10.8)	-1.3 (-11.1, 8.3)	3.3 (-6.9, 12.8)	5.8 (-5.3, 17.0)	3.3 (-5.0, 11.3)	4.1 (-4.3, 12.2)	0.3 (-2.8, 3.4)	20.0 (11.5, 28.5)	5.5 (-2.9, 13.4)	3.5 (-4.7, 11.7)	-0.6 (-12.6, 10.6)	3.4 (-5.1, 11.7)		-	-	-	-	
Ranij2 1mo	-1.1 (-3.9, 1.6)	-0.6 (-4.2, 2.9)	-	-1.5 (-5.1, 1.9)	-0.7 (-4.4, 2.9)	-	0.4 (-2.7, 3.5)	-3.6 (-9.4, 2.2)	0.9 (-5.1, 6.7)	3.4 (-4.2, 11.2)	0.9 (-2.1, 4.0)	1.8 (-1.7, 5.1)	-2.2 (-10.7, 6.9)	17.7 (13.5, 22.0)	3.1 (-0.9, 6.9)	1.1 (-1.6, 3.9)	-3.1 (-12.0, 5.6)	1.0 (-2.7, 4.5)	-2.4 (-10.8, 6.0)		-0.5 (-2.3, 1.3)	-	-	
Ranij2 Loading --> PRN <6wkly	-1.7 (-4.2, 0.9)	-1.2 (-4.8, 2.2)	-	-2.2 (-5.7, 1.3)	-1.3 (-4.7, 2.1)	-	-0.2 (-3.3, 2.8)	-4.2 (-10.2, 1.4)	0.2 (-5.6, 6.0)	2.8 (-4.9, 10.6)	0.2 (-2.7, 3.3)	1.1 (-2.2, 4.5)	-2.7 (-11.4, 6.2)	17.0 (12.9, 21.2)	2.5 (-1.4, 6.2)	0.5 (-2.1, 3.1)	-3.7 (-12.6, 5.1)	0.4 (-3.2, 4.0)	-3.0 (-11.2, 5.3)	-0.6 (-3.6, 2.3)		-	-	
Sham anti-VEGF	-17.6 (-20.3, -15.0)	-17.1 (-20.7, -13.7)	-	-18.1 (-21.7, -14.7)	-17.3 (-20.9, -13.7)	-	-16.2 (-19.4, -12.9)	-20.2 (-26.0, -14.3)	-15.8 (-21.7, -9.9)	-13.2 (-20.9, -5.3)	-15.7 (-19.0, -12.3)	-14.8 (-18.5, -11.3)	-18.7 (-27.2, -9.3)	1.1 (-3.3, 5.3)	-13.5 (-17.0, -10.0)	-15.5 (-18.6, -12.2)	-19.7 (-28.6, -10.8)	-15.6 (-19.3, -11.9)	-19.0 (-27.2, -10.4)	-16.6 (-20.3, -12.7)	-15.9 (-19.6, -12.3)		-	
Sham PDT	-23.3 (-27.3, -19.2)	-22.9 (-27.6, -18.0)	-	-23.9 (-28.4, -19.0)	-23.0 (-27.8, -18.1)	-	-21.9 (-26.5, -17.2)	-25.8 (-32.6, -19.4)	-21.4 (-28.3, -14.8)	-18.9 (-27.2, -10.5)	-21.4 (-25.9, -16.8)	-20.6 (-25.3, -15.8)	-24.4 (-33.6, -15.1)	-4.7 (-7.1, -2.2)	-19.3 (-24.1, -14.3)	-21.2 (-25.5, -16.7)	-25.5 (-35.1, -16.0)	-21.3 (-25.9, -16.5)	-24.7 (-33.4, -15.9)	-22.3 (-27.0, -17.4)	-21.7 (-26.4, -16.9)	-5.7 (-10.7, -0.7)	-	

Values given are mean differences. The segment below and to the left of the shaded cells is derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the mean of the posterior distribution, and numbers in parentheses are 95% credible intervals. The segment above and to the right of the shaded cells gives pooled direct evidence (random-effects pairwise meta-analysis), where available (column versus row). Numbers in parentheses are 95% confidence intervals.



1 **Figure 9: BCVA: mean difference at 12 months – relative effect of all options versus**
 2 **monthly ranibizumab 0.5mg**

3




4 **Figure 10: BCVA: mean difference at 12 months – expected absolute change**

1 **Table 13: BCVA: mean difference at 12 months – rankings for each comparator**

	Probability best	Median rank (95%CI)
Aflib 0.5 1mo	0.006	7 (2, 15)
Aflib 2 1mo	0.042	5 (1, 12)
Aflib 2 Loading --> 2mo	0.008	7 (2, 15)
Beva 1.25 1mo	0.000	10 (5, 15)
Beva 1.25 2mo	0.308	2 (1, 13)
Beva 1.25 6wk	0.003	12 (2, 17)
Beva 1.25 Loading --> 12wk	0.004	17 (3, 18)
Beva 1.25 Loading --> PRN	0.000	12 (6, 17)
Beva 1.25 PRN	0.000	15 (7, 18)
Beva 1.25 Treat and extend	0.139	4 (1, 18)
PDT PRN >6wkly	0.000	20 (19, 20)
Rani 0.5 1mo	0.003	6 (3, 10)
Rani 0.5 Loading --> 3mo	0.000	17 (9, 18)
Rani 0.5 Loading --> PRN	0.000	13 (7, 17)
Rani 0.5 Loading --> PRNX	0.327	3 (1, 18)
Rani 0.5 PRN	0.001	12 (5, 17)
Rani 0.5 Treat and extend	0.154	3 (1, 17)
Rani 2 1mo	0.004	9 (3, 16)
Rani 2 Loading --> PRN	0.002	11 (4, 17)
Sham anti-VEGF	0.000	19 (19, 20)
Sham PDT	0.000	21 (21, 21)
Aflib 0.5 1mo	0.006	7 (2, 15)

2



1 Figure 11: BCVA: mean difference at 12 months – rank probability histograms

1 G.2.1.1.2.2 24 months

2 Table 14: BCVA: mean difference at 24 months – relative effectiveness of all pairwise combinations

	Ran 0.5 1mo	Afib 0.5 1mo	Afib 0.5 Loading --> PRN <6wkly	Afib 2 1mo	Afib 2 Loading --> 2mo	Afib 2 Loading --> PRN <6wkly	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ran 0.5 Loading --> 3mo	Ran 0.5 Loading --> PRN <6wkly	Ran 0.5 Loading --> PRNX	Ran 0.5 PRN <6wkly	Ran 0.5 Treat and extend	Ran 2 1mo	Ran 2 Loading --> PRN <6wkly	Sham anti-VEGF	Sham PDT
Ran 0.5 1mo		-	-	-	-	-	-2.4 (-5.0, 0.3)	-	-	-	-2.8 (-6.1, 0.5)	-3.8 (-7.3, -0.3)	-	-19.2 (-22.7, -15.7)	-	-2.7 (-6.1, 0.7)	-	-2.1 (-5.3, 1.1)	-	-1.1 (-3.8, 1.6)	-1.5 (-4.0, 1.0)	-20.9 (-23.7, -18.1)	-
Afib 0.5 1mo	-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Afib 0.5 Loading --> PRN <6wkly	-1.0 (-3.9, 1.3)	-		-	-	1.0 (-0.5, 2.5)	-	-	-	-	-	-	-	-	-	1.3 (-0.5, 3.1)	-	-	-	-	-	-	-
Afib 2 1mo	-	-	-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Afib 2 Loading --> 2mo	-	-	-	-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Afib 2 Loading --> PRN <6wkly	-0.5 (-3.2, 1.7)	-	0.5 (-1.2, 2.3)	-	-		-	-	-	-	-	-	-	-	-	0.3 (-1.3, 1.8)	-	-	-	-	-	-	-
Beva 1.25 1mo	-1.3 (-4.1, 1.3)	-	-0.3 (-3.7, 3.4)	-	-	-0.8 (-4.1, 2.7)		-	-	-	0.9 (-2.4, 4.2)	-2.8 (-6.3, 0.7)	-	-	-	-1.0 (-4.6, 2.6)	-	-1.1 (-4.3, 2.1)	-	-	-	-	-
Beva 1.25 2mo	-	-	-	-	-	-	-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Beva 1.25 6wk	-	-	-	-	-	-	-	-		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Beva 1.25 Loading --> 12wk	-	-	-	-	-	-	-	-	-		-	-	-	-	-	-	-	-	-	-	-	-	-


Macular degeneration
Network meta-analysis

	Ranij0.5 1mo	Afibj0.5 1mo	Afibj0.5 Loading --> PRN <6wkly	Afibj2 1mo	Afibj2 Loading --> 2mo	Afibj2 Loading --> PRN <6wkly	Bevaj1.25 1mo	Bevaj1.25 2mo	Bevaj1.25 6wk	Bevaj1.25 Loading --> 12wk	Bevaj1.25 Loading --> PRN <6wkly	Bevaj1.25 PRN <6wkly	Bevaj1.25 Treat and extend	PDT PRN >6wkly	Ranij0.5 Loading --> 3mo	Ranij0.5 Loading --> PRN <6wkly	Ranij0.5 Loading --> PRNX	Ranij0.5 PRN <6wkly	Ranij0.5 Treat and extend	Ranij2 1mo	Ranij2 Loading --> PRN <6wkly	Sham anti-VEGF	Sham PDT
Bevaj1.25 Loading --> PRN <6wkly	-1.5 (-4.6, 1.5)	-	-0.5 (-4.0, 3.4)	-	-	-1.0 (-4.4, 2.7)	-0.2 (-3.5, 3.1)	-	-	-		-	-	-	-	-1.9 (-5.1, 1.3)	-	-	-	-	-	-	-
Bevaj1.25 PRN <6wkly	-3.7 (-7.2, -0.2)	-	-2.6 (-6.7, 1.7)	-	-	-3.2 (-7.1, 1.2)	-2.3 (-5.7, 1.2)	-	-	-	-2.2 (-6.2, 1.9)		-	-	-	-	-	1.7 (-1.1, 4.5)	-	-	-	-	-
Bevaj1.25 Treat and extend	-	-	-	-	-	-	-	-	-	-	-	-		-	-	-	-	-	-	-	-	-	-
PDT PRN >6wkly	-18.5 (-22.4, -14.5)	-	-17.5 (-22.0, -12.5)	-	-	-18.0 (-22.5, -13.1)	-17.1 (-21.9, -12.4)	-	-	-	-17.0 (-21.9, -12.1)	-14.8 (-20.1, -9.5)			-	-	-	-	-	-	-	-	-5.0 (-7.4, -2.7)
Ranij0.5 Loading --> 3mo	-	-	-	-	-	-	-	-	-	-	-	-	-	-		-	-	-	-	-	-	-	-
Ranij0.5 Loading --> PRN <6wkly	-2.4 (-5.1, 0.1)	-	-1.3 (-4.0, 1.4)	-	-	-1.8 (-4.4, 0.7)	-1.0 (-4.4, 2.1)	-	-	-	-0.8 (-3.9, 1.9)	1.3 (-2.8, 5.2)	-	16.1 (11.5 , 20.8)	-		-	-	-	0.1 (-2.6, 2.8)	-0.3 (-2.8, 2.2)	-	-
Ranij0.5 Loading --> PRNX	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		-	-	-	-	-	-
Ranij0.5 PRN <6wkly	-2.1 (-5.8, 1.4)	-	-1.1 (-5.3, 3.4)	-	-	-1.6 (-5.8, 2.7)	-0.8 (-4.3, 2.8)	-	-	-	-0.6 (-4.9, 3.6)	1.5 (-2.2, 5.1)	-	16.3 (10.9 , 21.6)	-	0.2 (-3.9, 4.5)	-		-	-	-	-	-
Ranij0.5 Treat and extend	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		-	-	-	-
Ranij2 1mo	-1.7 (-5.3, 1.7)	-	-0.6 (-4.6, 3.5)	-	-	-1.2 (-5.0, 2.7)	-0.4 (-4.7, 3.8)	-	-	-	-0.2 (-4.4, 4.0)	2.0 (-3.0, 6.7)	-	16.8 (11.5 , 22.0)	-	0.7 (-2.9, 4.2)	-	0.5 (-4.5, 5.1)	-		-0.4 (-3.1, 2.3)	-	-
Ranij2 Loading --> PRN <6wkly	-2.1 (-5.5, 1.1)	-	-1.1 (-4.8, 2.8)	-	-	-1.6 (-5.2, 2.1)	-0.8 (-4.8, 3.2)	-	-	-	-0.6 (-4.7, 3.4)	1.5 (-3.2, 6.2)	-	16.3 (11.3 , 21.5)	-	0.3 (-3.0, 3.6)	-	0.0 (-4.8, 4.8)	-	-0.4 (-4.1, 3.3)		-	-
Sham anti-VEGF	-21.3 (-24.5, -18.0)	-	-20.2 (-24.2, -15.8)	-	-	-20.7 (-24.6, -16.5)	-19.9 (-24.1, -15.6)	-	-	-	-19.4 (-24.1, -15.3)	-17.6 (-22.5, -12.7)	-	-2.8 (-7.9, 2.3)	-	-18.9 (-22.9, -14.6)	-	-19.1 (-24.0, -14.2)	-	-19.6 (-24.2, -14.6)	-19.2 (-23.6, -14.5)		-

Macular degeneration
Network meta-analysis


	Ranij0.5 1mo	Afibj0.5 1mo	Afibj0.5 Loading --> PRN <6wkly	Afibj2 1mo	Afibj2 Loading --> 2mo	Afibj2 Loading --> PRN <6wkly	Bevaj1.25 1mo	Bevaj1.25 2mo	Bevaj1.25 6wk	Bevaj1.25 Loading --> 12wk	Bevaj1.25 Loading --> PRN <6wkly	Bevaj1.25 PRN <6wkly	Bevaj1.25 Treat and extend	PDT PRN >6wkly	Ranij0.5 Loading --> 3mo	Ranij0.5 Loading --> PRN <6wkly	Ranij0.5 Loading --> PRNX	Ranij0.5 PRN <6wkly	Ranij0.5 Treat and extend	Ranij2 1mo	Ranij2 Loading --> PRN <6wkly	Sham anti-VEGF	Sham PDT
Sham PDT	-23.7 (-28.4, -18.8)	-	-22.6 (-28.0, -16.9)	-	-	-23.2 (-28.3, -17.5)	-22.3 (-27.8, -16.8)	-	-	-	-22.2 (-27.6, -16.6)	-20.0 (-25.8, -13.9)	-	-5.2 (-7.9, -2.4)	-	-21.3 (-26.5, -15.8)	-	-21.6 (-27.3, -15.5)	-	-22.0 (-27.7, -16.0)	-21.5 (-27.3, -15.8)	-2.4 (-8.2, 3.5)	

Values given are mean differences. The segment below and to the left of the shaded cells is derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the mean of the posterior distribution, and numbers in parentheses are 95% credible intervals. The segment above and to the right of the shaded cells gives pooled direct evidence (random-effects pairwise meta-analysis), where available (column versus row). Numbers in parentheses are 95% confidence intervals.



1 **Figure 12: BCVA: mean difference at 24 months – relative effect of all options versus**
2 **reference treatment**

3




4 **Figure 13: BCVA: mean difference at 24 months – expected absolute change**

1 **Table 15: BCVA: mean difference at 24 months – rankings for each comparator**

	Probability best	Median rank (95%CI)
Aflib 0.5 Loading --> PRN	0.054	4 (1, 9)
Aflib 2 Loading --> PRN	0.191	3 (1, 8)
Beva 1.25 1mo	0.079	5 (1, 9)
Beva 1.25 Loading --> PRN	0.083	5 (1, 10)
Beva 1.25 PRN	0.006	10 (3, 10)
PDT PRN >6wkly	0.000	11 (11, 12)
Rani 0.5 1mo	0.383	2 (1, 5)
Rani 0.5 Loading --> PRN	0.003	7 (3, 10)
Rani 0.5 PRN	0.068	7 (1, 10)
Rani 2 1mo	0.092	6 (1, 10)
Rani 2 Loading --> PRN	0.042	7 (1, 10)
Sham anti-VEGF	0.000	12 (11, 13)

2



1 **Figure 14: BCVA: mean difference at 24 months – rank probability histograms**

2

G.2.1.23 Categorical (5-category)

4 G.2.1.2.1 Model selection

5 Model fit statistics for 12- and 24-month 5-category NMAs are shown in Table 16.

6 As noted in G.1.1.4, once we had selected the optimal model for the most critical NMA
 7 (bivariate normal mean difference at 12 and 24 months; see G.2.1.1.1), model selection for
 8 other outcomes sought to disprove that this was the globally optimal model, rather than to
 9 establish what could be argued to be best for that particular outcome. In this instance, it was
 10 clear that the preferred (random-effects, MR4c) approach was better than fixed and/or

- 1 unadjusted models at 12 months, so we were happy to use the same approach for this
- 2 outcome.
- 3 For the 24-month synthesis, no data are available for TREX, PRNX or frequencies of routine
- 4 administration other than monthly (see G.2.1.1). Therefore, in this outcome (for which
- 5 separate analyses must be performed for the 2 timepoints), it is not possible to adjust for
- 6 these features in the 2-year analysis. Nevertheless a random-effects model that adjusted for
- 7 PRN and pre-PRN loading was seen to improve model fit compared with fixed-effects and/or
- 8 unadjusted approaches, so it was preferred.

1 **Table 16: BCVA: categorical (5-category) at 12 and 24 months – summary model fit statistics, showing selection of best-fitting models**

Outcome	Model for treatment differences	Number of discrete nodes	Model for category differences	Covariates					N	Total residual deviance	DIC	Standard deviation of random effects distributions (95%CrI)	
				PRN	Loading	TREX	PRNX	Frequency				Between treatments	Between categories
Categorical change in BCVA at 12mo (5-category split)	FIXED	20	FIXED						149	216.8	831.6	n/a	n/a
			RANDOM							174.2	806.3	n/a	0.16 (0.09, 0.26)
	RANDOM		FIXED							211.8	831.8	0.08 (0.004, 0.20)	n/a
			RANDOM							170.4	807.1	0.07 (0.005, 0.19)	0.16 (0.09, 0.27)
	RANDOM MR4c	7	FIXED	✓	✓	✓	✓	✓		211.2	824.5	0.07 (0.01, 0.16)	n/a
			RANDOM	✓	✓	✓	✓	✓		172.2	801.4	0.06 (0.004, 0.15)	0.15 (0.08, 0.25)
Categorical change in BCVA at 24mo (5-category split)	FIXED	12	FIXED						94	169.1	613.4	n/a	n/a
			RANDOM							105.3	563.5	n/a	0.18 (0.11, 0.30)
	RANDOM		FIXED							166.1	614.5	0.08 (0.004, 0.24)	n/a
			RANDOM							102.7	564.8	0.07 (0.004, 0.23)	0.18 (0.11, 0.30)
	RANDOM MR2	7	FIXED	✓	✓	n/a	n/a	n/a		165.2	610.4	0.06 (0.006, 0.18)	n/a
			RANDOM	✓	✓	n/a	n/a	n/a		102.0	560.7	0.06 (0.004, 0.17)	0.11 (0.07, 0.17)

MR4a = 1 covariate shared between anti-VEGF agents for frequency–response effect; MR4b = separate covariates for each anti-VEGF agent for frequency–response effect; MR4c = 1 covariate for aflibercept and 1 covariate for bevacizumab and ranibizumab for frequency–response effect;

2

1 G.2.1.2.2 Categorical change at 1 year (5-category; RE; meta-regression)

2 Table 17: BCVA: categorical change at 1 year (5-category; RE; meta-regression) – input data

Study	Change in ETRS letters		Aflib 0.5 1mo	Aflib 2 1mo	Aflib 2 Loading -> 2mo	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading -> 12wk	Beva 1.25 Loading -> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ranij 0.5 1mo	Ranij 0.5 Loading -> 3mo	Ranij 0.5 Loading -> PRN <6wkly	Ranij 0.5 Loading -> PRNX	Ranij 0.5 PRN <6wkly	Ranij 0.5 Treat and extend	Ranij 2 1mo	Ranij 2 Loading -> PRN <6wkly	Sham
	Minimum	Maximum																				
ANCHOR 2006	-29	-30											19	0								
	-14	-15											32	14								
	+15	+14											84	160								
	+15	+29											8	80								
	+30												0	26								
Barikian 2015	-14	-15							0	0												
	+15	+14							18	20												
									12	10												
BRAMD 2016	-14	-15				18								8								
	+15	+14				104								126								
						39								32								
CATT 2011	-14	-15				16					23			16				13				
	+15	+14				166					172			171				201				
						83					76			97				71				
El-Mollayess	+15	+14				39					36											
						21					24											
EXCITE 2010	-29	-30												0	4							
	+15	-15												6	14							
		+14												76	182							
														33	38							
GEFAL 2013	-14	-15							17							18						
	+15	+14							135							126						
									39							39						
HARBOR	-14	-15												6	15					18	14	
	+15	+14												174	177					157	169	
														95	83					99	90	
IVAN 2013	-29	-30				2				1				3	0							
	+15	-15				5				4				3	6							
		+14				108				106				98	108							
		+29				14				22				26	26							
		+30				5				3				10	3							

Macular degeneration
Network meta-analysis


Study	Change in ETDRS letters		Aflib 0.5 1mo	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ran 0.5 1mo	Ran 0.5 Loading --> 3mo	Ran 0.5 Loading --> PRN <6wkly	Ran 0.5 Loading --> PRNX	Ran 0.5 PRN <6wkly	Ran 0.5 Treat and extend	Ran 2 1mo	Ran 2 Loading --> PRN <6wkly	Sham
	Minimum	Maximum																				
LUCAS 2015	-15	-15										7							8			
	-14	+14										130							129			
	+15											47							50			
Lushchik 2013	-15	-15				3	0	6														
	-14	+14				37	47	43														
	+15					6	7	8														
MANTA 2013	-15	-15								8						10						
	-14	+14								110						118						
	+15									36					35							
MARINA	-15	-15											26									90
	-14	+14											312									136
	+15												140									12
NATTB 2013	-15	-15						3	5													
	-14	+14						41	44													
	+15							35	33													
PIER	-15	-15													16							32
	-14	+14													89							25
	+15														15							6
Sacu 2009	-15	-15							0			2										
	-14	+14							10			11										
	+15								4			1										
SALUTE 2015	-30	-30														2	1					
	-29	-15														2	3					
	-14	+14														26	21					
	+15															9	13					
Subramanian 2010	-30	-30								0						0						
	-29	-15								0						1						
	-14	-5								10						5						
	+15	+29								3						0						
	+30									2						1						
TAP 1999	-30	-30											59									49
	-29	-15											97									62
	-14	+14											222									91
	+15	+29											20									5
	+30												4									0

Macular degeneration
Network meta-analysis


Study	Change in ETDRS letters		Aflib 0.5 1mo	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ran 0.5 1mo	Ran 0.5 Loading --> 3mo	Ran 0.5 Loading --> PRN <6wkly	Ran 0.5 Loading --> PRNX	Ran 0.5 PRN <6wkly	Ran 0.5 Treat and extend	Ran 2 1mo	Ran 2 Loading --> PRN <6wkly	Sham
	Minimum	Maximum																				
TREX 2015		+14												17					30			
	+15													3					10			
VIEW 1&2 POOLED		-15	29	32	31									34								
	-14	+14	390	376	388									368								
	+15		178	205	188									193								
VIM 2005		-30											3									6
	-29	-15											7									12
	-14	+14											25									20
	+15												1									0
VIP 2001 Occ only		-30											37									30
	-29	-15											48									21
	-14	+14											76									39
	+15	+29											5									2
VIO		-30											39									20
	-29	-15											51									34
	-14												154									66

Where individual trials have more than 1 arm representing a treatment option, they have been pooled in this table for ease of interpretation, although they are entered as separate datapoints in the NMA.

- 1
- 2
- 3
- 4
- 5



1 **Figure 15: BCVA: categorical change at 1 year (5-category; RE; meta-regression) –**
2 **relative effect of all options versus sham**



3 **Figure 16: BCVA: categorical change at 1 year (5-category; RE; meta-regression) –**
4 **expected proportion of people in each category**

1 **Table 19: BCVA: categorical change at 1 year (5-category; RE; meta-regression) –**
2 **meta-regression coefficients**


Covariate		Beta	(95%CrI)
PRN		0.10	(-0.04, 0.24)
Loading		-0.01	(-0.19, 0.16)
TRES		-0.39	(-1.24, 0.41)
PRNX		-0.25	(-0.79, 0.29)
Frequency (per additional month)	Aflibercept	0.05	(-0.15, 0.24)
	Bevacizumab / ranibizumab	0.17	(0.06, 0.27)

Values on probit scale (z-scores); positive values indicate worse BCVA

3 **Table 20: BCVA: categorical change at 1 year (5-category; RE; meta-regression) –**
4 **rankings for each comparator**

	Probability best	Median rank (95%CI)
Sham	0.000	25 (25, 25)
Aflib 0.5	0.001	17 (7, 23)
Aflib 2	0.014	10 (2, 21)
Beva 1.25	0.008	8 (3, 15)
PDT	0.000	24 (24, 24)
Rani 0.5	0.021	7 (2, 12)
Rani 2	0.002	15 (5, 22)
Aflib 2; PRN	0.001	17 (4, 23)
Beva 1.25; PRN	0.000	13 (6, 22)
Rani 0.5; PRN	0.002	11 (4, 20)
Aflib 2; PRN+Load	0.001	16 (4, 23)
Beva 1.25; PRN+Load	0.000	12 (6, 21)
Rani 0.5; PRN+Load	0.002	10 (4, 19)
Aflib 2; TRES	0.186	3 (1, 23)
Beva 1.25; TRES	0.127	3 (1, 22)
Rani 0.5; TRES	0.329	2 (1, 21)
Aflib 2; PRNX	0.091	6 (1, 23)
Beva 1.25; PRNX	0.057	5 (1, 22)
Rani 0.5; PRNX	0.155	4 (1, 21)
Aflib 2; 2mo	0.000	13 (6, 19)
Beva 1.25; 2mo	0.000	17 (9, 21)
Rani 0.5; 2mo	0.000	15 (8, 20)
Aflib 2; 3mo	0.002	16 (5, 22)
Beva 1.25; 3mo	0.000	22 (16, 23)
Rani 0.5; 3mo	0.000	22 (15, 23)

5



1 **Figure 17: BCVA: categorical change at 1 year (5-category; RE; meta-regression) –**
2 **rank probability histograms**

3 **Table 21: BCVA: categorical change at 1 year (5-category; RE; meta-regression) –**
4 **model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	Between-study SD
171.3 (compared to 149 datapoints)	740.3	679.7	60.58	800.9	0.06 (95%CI: 0.00, 0.15)

5


1 G.2.1.2.3 Categorical change at 2 years (5-category; RE; meta-regression)

2 Table 22: BCVA: categorical change at 2 years (5-category; RE; meta-regression) –
3 input data


Study	Change in ETDRS letters		Aflib 0.5 Loading --> PRN <6wkly	Aflib 2 Loading --> PRN <6wkly	Beva 1.25 1mo	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	PDT PRN >6wkly	Ranij 0.5 1mo	Ranij 0.5 Loading --> PRN <6wkly	Ranij 0.5 PRN <6wkly	Ranij 2 1mo	Ranij 2 Loading --> PRN <6wkly	Sham
	Minimum	Maximum												
ANCHOR 2006		-30						23	2					
	-29	-15						26	29					
	-14	+14						85	144					
	+15	+29						6	73					
	+30							3	32					
CATT 2011		-15			10		29		9		19			
	-14	+14			78		151		81		164			
	+15				41		71		44		81			
HARBOR		-15							16	25		27	23	
	-14	+14							164	159		144	155	
	+15								95	91		103	95	
IVAN 2013		-30			4	0			4	4				
	-29	-15			8	11			4	11				
	-14	+14			90	95			84	98				
	+15	+29			19	15			32	18				
	+30				5	2			9	4				
MARINA		-15							43					112
	-14	+14							293					117
	+15								142					9
TAP 1999		-30						73						62
	-29	-15						116						67
	-14	+14						177						70
	+15	+29						33						8
	+30							3						0
VIEW 1&2 POOLED		-30	^a	^a						^a				
	-29	-15	^a	^a						^a				
	-14	+14	^a	^a						^a				
	+15	+29	^a	^a						^a				
	+30		^a	^a						^a				
VIM 2005		-30						4						13
	-29	-15						13						10
	-14	+14						12						13
	+15							3						1
VIO		-30						56						30
	-29	-15						59						34
	-14							129						56
VIP 2001 Occ only		-30						48						43
	-29	-15						43						20
	-14	+14						67						28
	+15	+29						8						1
VIP 2001 PC or MC		-30						19						11
	-29	-15						11						2
	-14							29						9

Where individual trials have more than 1 arm representing a treatment option, they have been pooled in this table for ease of interpretation, although they are entered as separate datapoints in the NMA.

^a Academic-in-confidence data supplied by the manufacturer of aflibercept to TA294, used with consent for this analysis



1 **Figure 18: BCVA: categorical change at 2 years (5-category; RE; meta-regression) –**
2 **relative effect of all options versus sham**



3 **Figure 19: BCVA: categorical change at 2 years (5-category; RE; meta-regression) –**
4 **expected proportion of people in each category**

1 **Table 24: BCVA: categorical change at 2 years (5-category; RE; meta-regression) –**
2 **meta-regression coefficients**

Covariate	Beta	(95%CrI)
PRN	0.10	(-0.11, 0.30)
Loading	0.03	(-0.22, 0.29)


Values on probit scale (z-scores); positive values indicate worse BCVA

3

4 **Table 25: BCVA: categorical change at 2 years (5-category; RE; meta-regression) –**
5 **rankings for each comparator**

	Probability best	Median rank (95%CI)
Sham	0.000	13 (13, 13)
Aflib 0.5	0.051	5 (1, 11)
Aflib 2	0.326	2 (1, 7)
Beva 1.25	0.011	7 (2, 10)
PDT	0.000	12 (12, 12)
Rani 0.5	0.125	3 (1, 6)
Rani 2	0.339	3 (1, 9)
Aflib 2; PRN	0.080	6 (1, 11)
Beva 1.25; PRN	0.004	10 (3, 11)
Rani 0.5; PRN	0.042	6 (1, 10)
Aflib 2; PRN+Load	0.014	7 (2, 11)
Beva 1.25; PRN+Load	0.001	10 (6, 11)
Rani 0.5; PRN+Load	0.006	7 (3, 10)

6



1 **Figure 20: BCVA: categorical change at 2 years (5-category; RE; meta-regression) –**
2 **rank probability histograms**

3

4 **Table 26: BCVA: categorical change at 2 years (5-category; RE; meta-regression) –**
5 **model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	Between-study SD
102 (compared to 94 datapoints)	521.6	482.5	39.13	560.7	0.06 (95%CI: 0.00, 0.17)

G.2.1.31 Categorical (10-category)

2 G.2.1.3.1 Model selection

3 Model fit statistics for 12- and 24-month 10-category NMAs are shown in Table 27.

4 As noted in G.1.1.4, once we had selected the optimal model for the most critical NMA
5 (bivariate normal mean difference at 12 and 24 months; see G.2.1.1.1.1), model selection for
6 other outcomes sought to disprove that this was the globally optimal model, rather than to
7 establish what could be argued to be best for that particular outcome. In this instance, it was
8 clear that the preferred (random-effects, MR4c) approach was better than fixed and/or
9 unadjusted models at 12 months, so we were happy to use the same approach for this
10 outcome.

11 For the 24-month synthesis, no data are available for TREX, PRNX or frequencies of routine
12 administration other than monthly (see G.2.1.1). Therefore, in this outcome (for which
13 separate analyses must be performed for the 2 timepoints), it is not possible to adjust for
14 these features in the 2-year analysis. Nevertheless a random-effects model that adjusted for
15 PRN and pre-PRN loading was seen to improve model fit compared with fixed-effects and/or
16 unadjusted approaches, so it was preferred.

1 Table 27: BCVA: categorical (10-category) at 12 and 24 months – summary model fit statistics, showing selection of best-fitting models

Outcome	Model for treatment differences	Number of discrete nodes	Model for category differences	Covariates					N	Total residual deviance	DIC	Standard deviation of random effects distributions (95%CrI)	
				PRN	Loading	TREX	PRNX	Frequency				Between treatments	Between categories
Categorical change in BCVA at 12mo (10-category split)	FIXED	20	FIXED						221	484.0	1392	n/a	n/a
			RANDOM							242.7	1188	n/a	0.14 (0.10, 0.19)
	RANDOM		FIXED							478.1	1392	0.08 (0.01, 0.18)	n/a
			RANDOM							237.5	1188	0.08 (0.01, 0.18)	0.14 (0.10, 0.19)
	RANDOM MR4c	7	FIXED	✓	✓	✓	✓	✓		479.3	1387	0.07 (0.01, 0.16)	n/a
			RANDOM	✓	✓	✓	✓	✓		241.6	1186	0.07 (0.01, 0.16)	0.13 (0.10, 0.18)
Categorical change in BCVA at 24mo (10-category split)	FIXED	12	FIXED						141	242.3	913.6	n/a	n/a
			RANDOM							162.3	852.7	n/a	0.09 (0.06, 0.13)
	RANDOM		FIXED							240.8	915.1	0.06 (0.004, 0.20)	n/a
			RANDOM							161.2	854.0	0.05 (0.004, 0.18)	0.08 (0.06, 0.13)
	RANDOM MR2	7	FIXED	✓	✓	n/a	n/a	n/a		240.2	911.7	0.05 (0.004, 0.16)	n/a
			RANDOM	✓	✓	n/a	n/a	n/a		160.8	851.4	0.04 (0.002, 0.14)	0.09 (0.06, 0.13)

MR4a = 1 covariate shared between anti-VEGF agents for frequency–response effect; MR4b = separate covariates for each anti-VEGF agent for frequency–response effect; MR4c = 1 covariate for aflibercept and 1 covariate for bevacizumab and ranibizumab for frequency–response effect;

2

1 G.2.1.3.2 Categorical change at 1 year (10-category; RE; meta-regression)

2 Table 28: BCVA: categorical change at 1 year (10-category; RE; meta-regression) – input data

	Change in ETRS letters		Aflib 0.5 1mo	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ranij 0.5 1mo	Ranij 0.5 Loading --> 3mo	Ranij 0.5 Loading --> PRN <6wkly	Ranij 0.5 Loading --> PRNX	Ranij 0.5 PRN <6wkly	Ranij 0.5 Treat and extend	Ranij 2 1mo	Ranij 2 Loading --> PRN <6wkly	Sham	
	Minimum	Minimum																					
ANCHOR 2006	-30	-15											19	0									
	-29	-1											32	14									
	-14	+14											49	54									
	0	+29											35	106									
	+15	+30											8	80									
												0	26										
Barikian 2015	-15								0	0													
	-14	+14							18	20													
	+15								12	10													
BRAMD 2016	-15					18								8									
	-14	+14				104								126									
	+15					39								32									
CATT 2011	-15					16					23			16				13					
	-14	-5				18					23			19				23					
	-4	+4				50					59			62				75					
	+5	+14				98					90			90				103					
	+15					83					76			97				71					
El-Mollayess	+14					39					36												
	+15					21					24												
EXCITE 2010	-30													0	4								
	-29	-15												6	14								
	-14	-1												14	55								
	0	+14												62	127								
	+15													33	38								
GEFAL 2013	-15								17								18						
	-14	-5							23								27						
	-4	+4							47								47						
	+5	+14							65								52						
	+15								39								39						

Macular degeneration

	Change in ETRS letters		Aflib 0.5 1mo	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ranij 0.5 1mo	Ranij 0.5 Loading --> 3mo	Ranij 0.5 Loading --> PRN <6wkly	Ranij 0.5 Loading --> PRNX	Ranij 0.5 PRN <6wkly	Ranij 0.5 Treat and extend	Ranij 2 1mo	Ranij 2 Loading --> PRN <6wkly	Sham
	Minimum	Minimum																				
HARBOR	-14	-15												6		15				18	14	
	+15	+14												174		177				157	169	
														95		83				99	90	
IVAN 2013	-29	-30				2				1				3		0						
	-14	-15				5				4				3		6						
	-4	-5				22				15				13		14						
	+5	+4				42				52				34		50						
	+15	+14				44				39				51		44						
	+30	+29				14				22				26		26						
LUCAS 2015	+5	-15										7								8		
	-4	-5										9								2		
	+5	+4										101								101		
	+15	+14										20								26		
												47								50		
Lushchik 2013	+5	-15				3	0	6														
	-4	-5				4	6	4														
	+15	+4				19	19	29														
	+5	+14				14	22	10														
	+15	+14				6	7	8														
MANTA 2013	+5	-15								8						10						
	-4	-5								24						25						
	+5	+4								32						43						
	+15	+14								54						50						
										36						35						
MARINA	+15	-15												26								90
	-14	+14												312								136
	+15	+14												140								12
NATTB 2013	+15	-15						3	5													
	-14	+14						41	44													
	+15	+14						35	33													
PIER	-14	-15													16							32
	+15	+14													89							25


Macular degeneration

	Change in ETRS letters		Aflib 0.5 1mo	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ranij 0.5 1mo	Ranij 0.5 Loading --> 3mo	Ranij 0.5 Loading --> PRN <6wkly	Ranij 0.5 Loading --> PRN PRNX	Ranij 0.5 PRN <6wkly	Ranij 0.5 Treat and extend	Ranij 2 1mo	Ranij 2 Loading --> PRN <6wkly	Sham
	Minimum	Minimum																				
	+15														15							6
Sacu 2009	-15								0				2									
	-14	-1							3				7									
	0	+14							7				4									
	+15								4				1									
SALUTE 2015		-30															2	1				
	-29	-15															2	3				
	-14	-1															11	5				
	0	+14															15	16				
	+15																9	13				
Subramanian 2010		-30							0								0					
	-29	-15							0								1					
	-14	-5							4								0					
	-4	+4							2								2					
	+5	+14							4								3					
	+15	+29							3								0					
	+30								2								1					
TAP 1999		-30											59									49
	-29	-15											97									62
	-14	-5											93									47
	-4	+4											87									34
	+5	+14											42									10
	+15	+29											20									5
+30												4									0	
TRES 2015		-10												0						3		
	-9	+9											11							24		
	+10	+14											6							3		
	+15												3							10		
VIEW 1&2 POOLED		-15	29	32	31									34								
	-14	+14	390	376	388									368								
	+15		178	205	188									193								
VIM 2005		-30											3									6
	-29	-15											7									12


Macular degeneration

	Change in ETDRS letters		Aflib 0.5 1mo	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Ranij 0.5 1mo	Ranij 0.5 Loading --> 3mo	Ranij 0.5 Loading --> PRN <6wkly	Ranij 0.5 Loading --> PRNX	Ranij 0.5 PRN <6wkly	Ranij 0.5 Treat and extend	Ranij 2 1mo	Ranij 2 Loading --> PRN <6wkly	Sham
	Minimum	Minimum																				
	-14	-5											14									8
	-4	+4											5									9
	+5	+14											6									3
	+15												1									0
VIO		-30											39									20
		-29	-15										51									34
		-14	-5										56									30
		-4	+4										51									24
		+5											47									12
VIP 2001 Occ only		-30											37									30
		-29	-15										48									21
		-14	-5										25									19
		-4	+4										36									15
		+5	+14										15									5
	+15	+29										5									2	
VIP 2001 PC or MC		-15											29									11
		-14											30									11

Where individual trials have more than 1 arm representing a treatment option, they have been pooled in this table for ease of interpretation, although they are entered as separate datapoints in the NMA.



1 **Figure 21: BCVA: categorical change at 1 year (10-category; RE; meta-regression) –**
 2 **relative effect of all options versus sham**



3 **Figure 22: BCVA: categorical change at 1 year (10-category; RE; meta-regression) –**
 4 **expected proportion of people in each category**

1 **Table 30: BCVA: categorical change at 1 year (10-category; RE; meta-regression) –**
 2 **meta-regression coefficients**


Covariate		Beta	(95%CrI)
PRN		0.10	(-0.05, 0.24)
Loading		-0.02	(-0.20, 0.17)
TREX		0.18	(-0.43, 0.81)
PRNX		-0.33	(-0.83, 0.18)
Frequency (per additional month)	Aflibercept	0.04	(-0.18, 0.26)
	Bevacizumab / ranibizumab	0.17	(0.07, 0.28)

Values on probit scale (z-scores); positive values indicate worse BCVA

3 **Table 31: BCVA: categorical change at 1 year (10-category; RE; meta-regression) –**
 4 **rankings for each comparator**

	Probability best	Median rank (95%CI)
Sham	0.000	25 (25, 25)
Aflib 0.5	0.002	16 (5, 22)
Aflib 2	0.031	9 (1, 20)
Beva 1.25	0.019	7 (2, 14)
PDT	0.000	24 (24, 24)
Rani 0.5	0.056	5 (1, 11)
Rani 2	0.006	14 (4, 21)
Aflib 2; PRN	0.004	16 (3, 23)
Beva 1.25; PRN	0.001	12 (4, 21)
Rani 0.5; PRN	0.006	10 (3, 19)
Aflib 2; PRN+Load	0.002	15 (3, 23)
Beva 1.25; PRN+Load	0.001	11 (4, 20)
Rani 0.5; PRN+Load	0.004	9 (3, 18)
Aflib 2; TREX	0.031	19 (1, 23)
Beva 1.25; TREX	0.020	16 (2, 23)
Rani 0.5; TREX	0.059	14 (1, 22)
Aflib 2; PRNX	0.209	3 (1, 22)
Beva 1.25; PRNX	0.127	3 (1, 20)
Rani 0.5; PRNX	0.413	2 (1, 18)
Aflib 2; 2mo	0.000	12 (5, 18)
Beva 1.25; 2mo	0.000	16 (9, 21)
Rani 0.5; 2mo	0.000	14 (7, 19)
Aflib 2; 3mo	0.007	15 (4, 22)
Beva 1.25; 3mo	0.000	22 (15, 23)
Rani 0.5; 3mo	0.000	21 (14, 23)

5



1 **Figure 23: BCVA: categorical change at 1 year (10-category; RE; meta-regression) –**
 2 **rank probability histograms**

3 **Table 32: BCVA: categorical change at 1 year (10-category; RE; meta-regression) –**
 4 **model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	Between-study SD
241.6 (compared to 221 datapoints)	1099	1011	87.33	1186	0.07 (95%CI: 0.01, 0.16)

1 G.2.1.3.3 Categorical change at 2 years (10-category; RE; meta-regression)

2 Table 33: BCVA: categorical change at 2 years (10-category; RE; meta-regression) –
3 input data

	Change in ETDRS letters		Aflib 0.5 Loading-->PRN	Aflib 2 Loading-->PRN	Beva 1.25 1mo	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	PDT PRN >6wkly	Ranil 0.5 1mo	Ranil 0.5 Loading --> PRN <6wkly	Ranil 0.5 PRN <6wkly	Ranil 2 1mo	Ranil 2 Loading --> PRN <6wkly	Sham
	Minimum	Minimum												
ANCHOR 2006	-30	-30						23	2					
	-29	-15						26	29					
	-14	-1						53	32					
	0	+14						32	112					
	+15	+29						6	73					
	+30						3	32						
CATT 2011	-15	-15			10		29		9		19			
	-14	+14			78		151		81		164			
	+15				41		71		44		81			
HARBOR	-15	-15							16	25		27	23	
	-14	+14							164	159		144	155	
	+15								95	91		103	95	
IVAN 2013	-30	-30			4	0			4	4				
	-29	-15			8	11			4	11				
	-14	-5			19	11			12	19				
	-4	+4			35	36			33	32				
	+5	+14			36	48			39	47				
	+15	+29			19	15			32	18				
	+30			5	2			9	4					
MARINA	-15	-15							43					112
	-14	+14							293					117
	+15								142					9
TAP 1999	-30	-30						73						62
	-29	-15						116						67
	-14	-5						92						31
	-4	+4						59						26
	+5	+14						26						13
	+15	+29						33						8
	+30						3						0	
VIEW 1&2 POOLED	-30	-30	^a	^b						^b				
	-29	-15	^b	^b						^b				
	-14	-10	^b	^b						^b				
	-9	-5	^b	^b						^b				
	-4	-1	^b	^b						^b				
	0	+4	^b	^b						^b				
	+5	+9	^b	^b						^b				
	+10	+14	^b	^b						^b				
+15	+29	^b	^b						^b					
	+30	^b	^b						^b					
VIM 2005	-30	-30						4						13
	-29	-15						13						10
	-14	-5						4						5
	-4	+4						4						5
	+5	+14						4						3
	+15						3						1	
VIO	-30	-30						56						30
	-29	-15						59						34
	-14	-5						43						30
	-4	+4						48						19
	+5						38						7	
VIP 2001 Occ only	-30	-30						48						43
	-29	-15						43						20

^a Academic-in-confidence data supplied by the manufacturer of aflibercept to TA294, used with consent for this analysis


	Change in ETDRS letters		Aflib 0.5 Loading-->PRN	Aflib 2 Loading -->PRN	Beva 1.25 1mo	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	PDT PRN >6wkly	Ran 0.5 1mo	Ran 0.5 Loading --> PRN <6wkly	Ran 0.5 PRN <6wkly	Ran 2 1mo	Ran 2 Loading --> PRN <6wkly	Sham
	Minimum	Minimum												
	-14	-5						29						10
	-4	+4						25						14
	+5	+14						13						4
	+15	+29						8						1
VIP 2001		-30						19						11
PC or	-29	-15						11						2
MC	-14							29						9

Where individual trials have more than 1 arm representing a treatment option, they have been pooled in this table for ease of interpretation, although they are entered as separate datapoints in the NMA.

1 Table 34: BCVA: categorical change at 2 years (10-category; RE; meta-regression) – relative effectiveness of all pairwise combinations


Sham																				
-1.26 (-1.51, -1.02)	Aflib 0.5																			
-1.35 (-1.58, -1.12)	-0.09 (-0.23, 0.06)	Aflib 2																		
-1.24 (-1.46, -1.02)	0.03 (-0.19, 0.25)	0.11 (-0.09, 0.31)	Beva 1.25																	
-0.31 (-0.43, -0.18)	0.95 (0.70, 1.19)	1.04 (0.80, 1.27)	0.93 (0.70, 1.15)	PDT																
-1.35 (-1.52, -1.17)	-0.09 (-0.26, 0.08)	0.00 (-0.15, 0.15)	-0.11 (-0.25, 0.02)	-1.04 (-1.21, -0.86)	Rani 0.5															
-1.36 (-1.61, -1.12)	-0.10 (-0.33, 0.14)	-0.01 (-0.24, 0.21)	-0.12 (-0.34, 0.09)	-1.05 (-1.29, -0.81)	-0.01 (-0.18, 0.15)	Rani 2														
-1.25 (-1.55, -0.94)	0.01 (-0.24, 0.26)	0.10 (-0.10, 0.29)	-0.02 (-0.30, 0.27)	-0.94 (-1.24, -0.63)	0.09 (-0.15, 0.34)	0.11 (-0.19, 0.40)	Aflib 2 PRN													
-1.14 (-1.43, -0.85)	0.12 (-0.17, 0.41)	0.21 (-0.07, 0.48)	0.10 (-0.10, 0.29)	-0.83 (-1.12, -0.53)	0.21 (-0.03, 0.45)	0.22 (-0.07, 0.51)	0.11 (-0.09, 0.31)	Beva 1.25 PRN												
-1.25 (-1.51, -0.99)	0.01 (-0.25, 0.27)	0.10 (-0.14, 0.33)	-0.02 (-0.26, 0.22)	-0.94 (-1.20, -0.68)	0.10 (-0.10, 0.29)	0.11 (-0.15, 0.36)	0.00 (-0.15, 0.15)	-0.11 (-0.25, 0.02)	Rani 0.5 PRN											
-1.25 (-1.51, -0.99)	0.01 (-0.18, 0.20)	0.10 (-0.03, 0.22)	-0.01 (-0.25, 0.22)	-0.94 (-1.20, -0.68)	0.09 (-0.09, 0.29)	0.11 (-0.14, 0.37)	0.00 (-0.23, 0.23)	-0.11 (-0.41, 0.19)	0.00 (-0.27, 0.27)	Aflib 2 PRN+Load										
-1.14 (-1.40, -0.88)	0.12 (-0.13, 0.37)	0.21 (-0.03, 0.44)	0.10 (-0.03, 0.22)	-0.83 (-1.09, -0.57)	0.21 (0.02, 0.39)	0.22 (-0.03, 0.47)	0.11 (-0.20, 0.42)	0.00 (-0.23, 0.23)	0.11 (-0.16, 0.38)	0.11 (-0.09, 0.31)	Beva 1.25 PRN+Load									
-1.25 (-1.47, -1.03)	0.01 (-0.20, 0.22)	0.10 (-0.10, 0.29)	-0.02 (-0.20, 0.17)	-0.94 (-1.16, -0.72)	0.10 (-0.03, 0.22)	0.11 (-0.10, 0.31)	0.00 (-0.28, 0.28)	-0.11 (-0.38, 0.15)	0.00 (-0.23, 0.23)	0.00 (-0.15, 0.15)	-0.11 (-0.25, 0.02)	Rani 0.5 PRN+Load								

Values given are z-scores (negative numbers favour the option on the right; positive numbers favour the option above)
 Data are derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects. The point estimate reflects the mean of the posterior distribution, and numbers in parentheses are 95% credible intervals.



1 **Figure 24: BCVA: categorical change at 2 years (10-category; RE; meta-regression) –**
 2 **relative effect of all options versus common comparator**

3



4 **Figure 25: BCVA: categorical change at 2 years (10-category; RE; meta-regression) –**
 5 **expected proportion of people in each category**

6

1 **Table 35: BCVA: categorical change at 2 years (5-category; RE; meta-regression) –**
 2 **meta-regression coefficients**


Covariate	Beta	(95%CrI)
PRN	0.10	(-0.10, 0.29)
Loading	0.00	(-0.23, 0.23)

Values on probit scale (z-scores); positive values indicate worse BCVA

3 **Table 36: BCVA: categorical change at 2 years (10-category; RE; meta-regression) –**
 4 **rankings for each comparator**

	Probability best	Median rank (95%CI)
Sham	0.000	13 (13, 13)
Aflib 0.5	0.030	6 (1, 11)
Aflib 2	0.257	3 (1, 8)
Beva 1.25	0.014	7 (2, 10)
PDT	0.000	12 (12, 12)
Rani 0.5	0.161	3 (1, 6)
Rani 2	0.395	2 (1, 9)
Aflib 2; PRN	0.062	6 (1, 11)
Beva 1.25; PRN	0.004	10 (3, 11)
Rani 0.5; PRN	0.046	6 (1, 10)
Aflib 2; PRN+Load	0.017	6 (2, 11)
Beva 1.25; PRN+Load	0.002	10 (5, 11)
Rani 0.5; PRN+Load	0.013	6 (2, 10)

5



1 **Figure 26: BCVA: categorical change at 2 years (10-category; RE; meta-regression) –**
 2 **rank probability histograms**

3

4 **Table 37: BCVA: categorical change at 2 years (10-category; RE; meta-regression) –**
 5 **model fit statistics**

Residual deviance	Dbar	Dhat	pD	DIC	tau
160.8 (compared to 141 datapoints)	802.4	753.8	48.61	851	0.04 (95%CI: 0.00, 0.14)

6

G.2.21 Discontinuation

G.2.2.12 Model selection

3 Model fit statistics for the discontinuation NMA are shown in Table 16.


4 As noted in G.1.1.4, once we had selected the optimal model for the most critical NMA
5 (bivariate normal mean difference at 12 and 24 months; see G.2.1.1.1.1), model selection for
6 other outcomes sought to disprove that this was the globally optimal model, rather than to
7 establish what could be argued to be best for that particular outcome. In this instance, it was
8 clear that the preferred (random-effects, MR4c) approach was no worse than fixed and/or
9 unadjusted models, so we were happy to use the same approach for this outcome.

1 **Table 38: BCVA: categorical (5-category) at 12 and 24 months – summary model fit**
 2 **statistics, showing selection of best-fitting models**

Outcome	Model for treatment differences	Number of discrete nodes	Covariates					N	Total residual deviance	DIC	Standard deviation of random effects distribution (95%CrI)
			PRN	Loading	TREX	PRNX	Frequency				
Probability of discontinuation at 12mo	FIXED	20						65.34	355.9	n/a	
	FIXED MR4c	7	✓	✓	✓	✓	59	72.75	356.5	n/a	
	RANDOM	20						61.88	357.2	0.22 (0.01, 0.67)	
	RANDOM MR4c	7	✓	✓	✓	✓		62.82	355.1	0.29 (0.03, 0.62)	

MR4c = 1 covariate for aflibercept and 1 covariate for bevacizumab and ranibizumab for frequency–response effect

G.2.2.23 **Probability of discontinuation at 1 year (RE; meta-regression)**



4 **Figure 27: Probability of discontinuation at 1 year (RE; meta-regression) – evidence**
 5 **network**


1 Table 39: Probability of discontinuation at 1 year (RE; meta-regression) – input data

	Rani 0.5 1mo	Rani 0.5 Loading --> 3mo	Rani 0.5 Loading --> PRN <6wkly	Rani 0.5 Loading --> PRNX	Rani 0.5 PRN <6wkly	Rani 0.5 Treat and extend	Rani 2 1mo	Rani 2 Loading --> PRN <6wkly	Aflib 0.5 1mo	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Sham
ANCHOR 2006	14/280																		13/140	
BISWAS 2011			8/62													10/60				
BRAMD 2016	29/166											34/166								
CATT 2011	17/301				13/298							21/286					29/300			
EXCITE 2010	12/115	37/238																		
GEFAL 2013			56/239													55/246				
HARBOR	21/275		16/275				18/274	18/273												
IVAN 2013	17/157		12/155									15/149				9/145				
LUCAS 2015						34/221												36/220		
Lushchik 2013												18/64	10/64	6/63						
MANTA 2013			36/163													33/154				
MARINA	16/478																			26/238
NATTB 2013														12/94	12/91					
PIER		4/121																		9/63
Sacu 2009																0/14			1/14	


Macular degeneration

	Rani 0.5 1mo	Rani 0.5 Loading --> 3mo	Rani 0.5 Loading --> PRN <6wkly	Rani 0.5 Loading --> PRNX	Rani 0.5 PRN <6wkly	Rani 0.5 Treat and extend	Rani 2 1mo	Rani 2 Loading --> PRN <6wkly	Aflib 0.5 1mo	Aflib 2 1mo	Aflib 2 Loading --> 2mo	Beva 1.25 1mo	Beva 1.25 2mo	Beva 1.25 6wk	Beva 1.25 Loading --> 12wk	Beva 1.25 Loading --> PRN <6wkly	Beva 1.25 PRN <6wkly	Beva 1.25 Treat and extend	PDT PRN >6wkly	Sham
SALUTE 2015			6/45	10/48																
Subramanian 2010			1/8													5/20				
TAP 1999																			23/402	13/207
TREX 2015	1/20					6/40														
VIEW 1&2 POOLED	71/609								82/615	58/617	81/616									
VIM 2005																			3/39	2/40
VIO																			25/244	9/120
VIP 2001 ALL																			15/225	10/114

Where individual trials have more than 1 arm representing a treatment option, they have been pooled in this table for ease of interpretation, although they are entered as separate datapoints in the NMA.



1 **Figure 28: Probability of discontinuation at 1 year (RE; meta-regression) – relative**
2 **effect of all options versus sham**



3 **Figure 29: Probability of discontinuation at 1 year (RE; meta-regression) – absolute**
4 **discontinuation rates**

1 **Table 41: Probability of discontinuation at 1 year (RE; meta-regression) – meta-**
2 **regression coefficients**


Covariate		Beta	(95%CrI)
PRN		0.07	(-0.48, 0.61)
Loading		-0.40	(-1.12, 0.31)
TREX		1.70	(-0.60, 4.97)
PRNX		0.57	(-0.74, 1.92)
Frequency (per additional month)	Aflibercept	0.38	(-0.40, 1.17)
	Bevacizumab / ranibizumab	0.02	(-0.31, 0.33)

Values on ln(odds) scale; positive values indicate higher probability of dropout

3 **Table 42: Probability of discontinuation at 1 year (RE; meta-regression) – rankings for**
4 **each comparator**

	Probability best	Median rank (95%CI)
Sham	0.000	22 (18, 25)
Aflib 0.5	0.006	15 (4, 23)
Aflib 2	0.024	4 (2, 19)
Beva 1.25	0.001	14 (5, 21)
PDT	0.000	22 (17, 25)
Rani 0.5	0.001	11 (4, 18)
Rani 2	0.031	11 (1, 21)
Aflib 2; PRN	0.073	4 (1, 21)
Beva 1.25; PRN	0.002	16 (5, 22)
Rani 0.5; PRN	0.010	13 (3, 21)
Aflib 2; PRN+Load	0.518	1 (1, 16)
Beva 1.25; PRN+Load	0.021	8 (2, 18)
Rani 0.5; PRN+Load	0.065	6 (1, 15)
Aflib 2; TREX	0.035	21 (1, 25)
Beva 1.25; TREX	0.001	24 (6, 25)
Rani 0.5; TREX	0.005	24 (4, 25)
Aflib 2; PRNX	0.148	5 (1, 23)
Beva 1.25; PRNX	0.006	18 (3, 25)
Rani 0.5; PRNX	0.023	16 (2, 24)
Aflib 2; 2mo	0.000	7 (4, 18)
Beva 1.25; 2mo	0.000	15 (7, 20)
Rani 0.5; 2mo	0.000	11 (5, 17)
Aflib 2; 3mo	0.018	15 (2, 23)
Beva 1.25; 3mo	0.004	15 (4, 22)
Rani 0.5; 3mo	0.009	12 (3, 20)

5



1 **Figure 30: Probability of discontinuation at 1 year (RE; meta-regression) – rank**
2 **probability histograms**

3

4 **Table 43: Probability of discontinuation at 1 year (RE; meta-regression) – model fit**
5 **statistics**

Residual deviance	Dbar	Dhat	pD	DIC	sd
62.82 (compared to 59 datapoints)	311.6	268.1	43.51	355.1	0.29 (95%CI: 0.03, 0.62)

6

G.3.1 References

- 2 Achana FA, Cooper NJ, Bujkiewicz S, Hubbard SJ, Kendrick D, Jones DR and Sutton
3 AJ. Network meta-analysis of multiple outcome measures accounting for borrowing of
4 information across outcomes. BMC Medical Research Methodology 2014;14:92.
- 5 Bujkiewicz S, Thompson JR, Riley RD, Abrams KR. Bayesian meta-analytical methods to
6 incorporate multiple surrogate endpoints in drug development process. Statistics in Medicine,
7 2016; 35 (7): 1063–89.
- 8 Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E. NICE DSU Technical Support Document 2:
9 A generalised linear modelling framework for pairwise and network meta-analysis of
10 randomised controlled trials. 2011; last updated September 2016; available from
11 <http://www.nicesdu.org.uk>
- 12 Dias, S., Sutton, A.J., Welton, N.J., Ades, A.E. NICE DSU Technical Support Document 3:
13 Heterogeneity: subgroups, meta-regression, bias and bias-adjustment. 2011; last updated
14 April 2012; available from <http://www.nicesdu.org.uk>
- 15 Dias, S., Welton, N.J., Sutton, A.J., Ades, A.E. NICE DSU Technical Support Document 5:
16 Evidence synthesis in the baseline natural history model. 2011; last updated April 2012;
17 available from <http://www.nicesdu.org.uk>
- 18 Franchini AJ, Dias S, Ades AE, Jansen JP, Welton NJ. Accounting for correlation in network
19 meta-analysis with multi-arm trials. Research synthesis methods. 2012 Jun 1;3(2):142-60.
- 20 Lu G, Ades AE, Sutton AJ, Cooper NJ, Briggs AH, Caldwell DM. Meta-analysis of mixed
21 treatment comparisons at multiple follow-up times. Statistics in medicine. 2007 Sep
22 10;26(20):3681-99.
- 23 Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model
24 complexity and fit. Journal of the Royal Statistical Society: Series B (Statistical Methodology).
25 2002 Oct 1;64(4):583-639.
- 26

G.4.7 OpenBUGS code

28 Code is provided below for the NMA and baseline synthesis models that were selected for
29 use in the guideline +/- health economic model. In several respects, this code is written in
30 such a way as to facilitate different models being run by changing input data rather than by
31 altering model code itself. Other models described in the 'model selection' tables above used
32 identical or similar code, but have not been reproduced here, for clarity's sake.

G.4.1.3 Network meta-analyses

G.4.1.1.4 Continuous data

```
35 Bivariate normal model for 1- and 2-year data, with provision for SMD and meta-  
36 regression (random effects)  
37  
38 # Bivariate normal likelihood; identity link  
39 # Random-effects model for multi-arm trials  
40 # based on  
41 # Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.  
42 # NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework  
43 # for Pairwise and Network Meta-Analysis of Randomised Controlled Trials.  
44 # 2011; last updated September 2016.  
45 # and  
46 # Dias, S., Sutton, A.J., Welton, N.J. & Ades, A.E.  
47 # NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression,  
48 # bias and bias-adjustment. 2011; last updated April 2012.
```

```

# http://www.nicesdu.org.uk
#
# This model will generate results on a natural scale if blnSMD is set to 0,
# and an SMD scale if blnSMD is set to 1
# It will include covariates if numCovars is set to > 1 and blnCovars != c(0,0,0,0)
# blnCovars[1] is a switch for PRN
# blnCovars[2] is a switch for Load
# blnCovars[3] is a switch for TREX and PRNX
# blnCovars[4] is a switch for Frequency
# Outputs are calculated with and without covariates for treatments identified in core c()

model {
  for(i in 1:NumStudies.0_12only) {
    mu[i,1] ~ dnorm(0, .0001) # indexes studies
    w[i,1,1] <- 0 # vague priors for trial baselines
    delta[i,1,1] <- 0 # multi-arm adjustment = 0 for Rx1
    pooled.SD.n[i,1] <- sum(SMD.SD.n[i,1:NumArms[i],1]) # treatment effect is 0 for Rx1
    pooled.SD.d[i,1] <- sum(SMD.SD.d[i,1:NumArms[i],1]) # sum SMD numerators
    pooled.SD[i,1] <- sqrt(pooled.SD.n[i,1] / pooled.SD.d[i,1]) # sum SMD denominators

    for (j in 1:NumArms[i]) {
      MC[i,j,1] ~ dnorm(phi[i,j,1], prec[i,j,1]) # pooled SD across all arms
      se[i,j,1] <- SD[i,j,1] / sqrt(N[i,j,1]) # indexes arms
      var[i,j,1] <- pow(se[i,j,1], 2) # normal likelihood
      prec[i,j,1] <- 1/var[i,j,1] # set SEs
      SMD.SD.d[i,j,1] <- N[i,j,1]-1 # set variances
      SMD.SD.n[i,j,1] <- SMD.SD.d[i,j,1] * pow(SD[i,j,1],2) # set precisions
      # pooled SD denom contribution

      phi[i,j,1] <- theta[i,j,1] * (pooled.SD[i,1] * blnSMD + (1 - blnSMD)) # pooled SD num contribution
      # convert to SMD (if desired)

      theta[i,j,1] <- mu[i,1]
        + delta[i,j,1]
        + beta.PRN[1] * (PRN[i,j,1] - PRN[i,1,1])
        + beta.TREX[1] * (TREX[i,j,1] - TREX[i,1,1])
        + beta.PRNX[1] * (PRNX[i,j,1] - PRNX[i,1,1])
        + beta.Load[1] * (Load[i,j,1]*PRN[i,j,1] - Load[i,1,1]*PRN[i,1,1])
        + (beta.Freq[betaID[Rx[i,j,1]],1] * Freq[i,j,1])
        - (beta.Freq[betaID[Rx[i,1,1]],1] * Freq[i,1,1])
      # linear predictor with covariates

      dev[i,j] <- (MC[i,j,1] - phi[i,j,1]) * (MC[i,j,1] - phi[i,j,1]) * prec[i,j,1] # deviance contribution
    } # close arm loop
    for (j in 2:NumArms[i]) {
      tau[i,j,1] <- tau[1] *2*(j-1)/j # indexes arms
      delta[i,j,1] ~ dnorm(md[i,j,1], tau[i,j,1]) # precision of MD dists, with MAC
      md[i,j,1] <- d[Rx[i,j,1],1] - d[Rx[i,1,1],1] + sw[i,j,1] # trial-specific MD distributions
      # mean of MD dists, with MAC

      w[i,j,1] <- (delta[i,j,1] - d[Rx[i,j,1],1] + d[Rx[i,1,1],1]) # multi-arm correction ("MAC")
      sw[i,j,1] <- sum(w[i,1:j-1,1])/(j-1) # cumulative MAC
    } # close arm loop
    resdev[i] <- sum(dev[i,1:NumArms[i]]) # trial-level deviance contribution
  } # close study loop

  for(i in NumStudies.0_12only+1:NumStudies) {
    for (k in 1:2) {
      mu[i,k] ~ dnorm(0, .0001) # indexes studies with 0-24 data
      w[i,1,1+(k-1)*2] <- 0 # indexes timepoints
      delta[i,1,1+(k-1)*2] <- 0 # vague priors for trial baselines
      pooled.SD.n[i,k] <- sum(SMD.SD.n[i,1:NumArms[i],k]) # multi-arm adjustment = 0 for Rx1
      pooled.SD.d[i,k] <- sum(SMD.SD.d[i,1:NumArms[i],k]) # treatment effect is 0 for Rx1
      pooled.SD[i,k] <- sqrt(pooled.SD.n[i,k] / pooled.SD.d[i,k]) # sum SMD numerators
      # sum SMD denominators

      mu[i,3] <- mu[i,2] - mu[i,1] # pooled SD across all arms
      # close timepoint loop
      for (j in 1:NumArms[i]) {
        MC[i,j,1:2] ~ dmnorm(phi[i,j,1:2], mvnPrec[i,j,,]) # indexes arms
        vcov[i,j,1,1] <- var[i,j,1] # mvnormal likelihood
        vcov[i,j,2,1] <- var[i,j,1] # vcov[1,1]
        vcov[i,j,1,2] <- var[i,j,1] # vcov[2,1]
        vcov[i,j,2,2] <- var[i,j,2] # vcov[1,2]
        mvnPrec[i,j,1:2,1:2] <- inverse(vcov[i,j,,]) # vcov[2,2]
        # convert vcov matrix to precision
        for (k in 1:2) {
          se[i,j,k] <- SD[i,j,k] / sqrt(N[i,j,k]) # indexes timepoints
          var[i,j,k] <- pow(se[i,j,k], 2) # set SEs
          prec[i,j,k] <- 1/var[i,j,k] # set variances
          SMD.SD.d[i,j,k] <- N[i,j,k]-1 # set precisions
          SMD.SD.n[i,j,k] <- SMD.SD.d[i,j,k] * pow(SD[i,j,k],2) # pooled SD denom contribution
          # pooled SD num contribution

          phi[i,j,k] <- theta[i,j,k] * (pooled.SD[i,k] * blnSMD + (1 - blnSMD)) # convert to SMD (if desired)

          theta[i,j,1+(k-1)*2] <- mu[i,1+(k-1)*2]
            + delta[i,j,1+(k-1)*2]
            + beta.PRN[1+(k-1)*2]
              * (PRN[i,j,1+(k-1)*2] - PRN[i,1,1+(k-1)*2])
            + beta.TREX[1+(k-1)*2]
              * (TREX[i,j,1+(k-1)*2] - TREX[i,1,1+(k-1)*2])
            + beta.PRNX[1+(k-1)*2]
              * (PRNX[i,j,1+(k-1)*2] - PRNX[i,1,1+(k-1)*2])
            + beta.Load[1+(k-1)*2]
  
```



```

* (Load[i,j,1+(k-1)*2]*PRN[i,j,1+(k-1)*2]
- Load[i,1,1+(k-1)*2]*PRN[i,1,1+(k-1)*2])
+ (beta.Freq[betaID[Rx[i,j,1+(k-1)*2]],1+(k-1)*2]
* Freq[i,j,1+(k-1)*2])
- (beta.Freq[betaID[Rx[i,1,1+(k-1)*2]],1+(k-1)*2]
* Freq[i,1,1+(k-1)*2]) # linear predictor with covariates
} # close timepoint loop
delta[i,j,2] <- delta[i,j,1] + delta[i,j,3] # sum yr1 effect and yr2 change
theta[i,j,2] <- theta[i,j,1] + theta[i,j,3] # theta for (0,2) is (0,1)+(1,2)
dev[i,j] <- mvnPrec[i,j,1,1]*pow(MC[i,j,1] - phi[i,j,1],2)
+ mvnPrec[i,j,2,2]*pow(MC[i,j,2] - phi[i,j,2],2)
+ 2*mvnPrec[i,j,1,2]*(MC[i,j,1] - phi[i,j,1])*(MC[i,j,2] - phi[i,j,2])
# deviance contribution
} # close arm loop
for (j in 2:NumArms[i]) { # indexes arms
for (k in 1:2) { # indexes timepoints
taud[i,j,1+(k-1)*2] <- tau[1+(k-1)*2]*2*(j-1)/j # precision of MD dists, with MAC
md[i,j,1+(k-1)*2] <- d[Rx[i,j,1+(k-1)*2],1+(k-1)*2]
- d[Rx[i,1,1+(k-1)*2],1+(k-1)*2]
+ sw[i,j,1+(k-1)*2] # mean of MD dists, with MAC
w[i,j,1+(k-1)*2] <- delta[i,j,1+(k-1)*2]
- d[Rx[i,j,1+(k-1)*2],1+(k-1)*2]
+ d[Rx[i,1,1+(k-1)*2],1+(k-1)*2]
sw[i,j,1+(k-1)*2] <- sum(w[i,1:j-1,1+(k-1)*2])/(j-1) # multi-arm correction ("MAC")
} # cumulative MAC
} # close timepoint loop
delta[i,j,1] ~ dnorm(md[i,j,1], taud[i,j,1]) # trial-specific MD distributions
delta[i,j,3] ~ dnorm(md[i,j,3], taud[i,j,3]) # trial-specific MD distributions
} # close arm loop
resdev[i] <- sum(dev[i,1:NumArms[i]]) # trial-level deviance contribution
} # close 0-24 study loop
totresdev <- sum(resdev[]) # total residual deviance

# priors
for (k in 1:2) { # indexes timepoints
d[1,1+(k-1)*2] <- 0 # effect is 0 for Rx1
for (j in 2:NumRx) { # indexes treatments
d.prior[j,1+(k-1)*2] ~ dnorm(0, .0001) # vague priors, treatment effects
d[j,1+(k-1)*2] <- d.prior[j,1+(k-1)*2] * nRx[j,1+(k-1)*2] # set effect to 0 if no evidence
} # close treatment loop
sdu[1+(k-1)*2] ~ dunif(RFXpriorParam1, RFXpriorParam2) # uniform between-trial prior
sdn[1+(k-1)*2] ~ dnorm(RFXpriorParam1, RFXpriorParam2) # normal between-trial prior
sdl[1+(k-1)*2] ~ dlnorm(RFXpriorParam1, RFXpriorParam2) # lognormal between-trial prior
sd[1+(k-1)*2] <- sdu[1+(k-1)*2] * equals(RFXpriorD,1)
+ sdn[1+(k-1)*2] * equals(RFXpriorD,2)
+ sdl[1+(k-1)*2] * equals(RFXpriorD,3) # choose desired prior
tau[1+(k-1)*2] <- pow(sd[1+(k-1)*2],-2) # between-trial precision
b.PRN[1+(k-1)*2] ~ dnorm(0, .001) # prior for PRN coefficient
b.Load[1+(k-1)*2] ~ dnorm(0, .001) # prior for loading coefficient
b.PRNX[1+(k-1)*2] ~ dnorm(0, .001) # prior for PRNX coefficient
b.TREX[1+(k-1)*2] ~ dnorm(0, .001) # prior for TREX coefficient
beta.PRN[1+(k-1)*2] <- b.PRN[1+(k-1)*2]
* blnCovars[1] * nCo[1,1+(k-1)*2] # 'turn off' if no data
beta.Load[1+(k-1)*2] <- b.Load[1+(k-1)*2]
* blnCovars[2] * nCo[2,1+(k-1)*2] # 'turn off' if no data
beta.PRNX[1+(k-1)*2] <- b.PRNX[1+(k-1)*2]
* blnCovars[3] * nCo[3,1+(k-1)*2] # 'turn off' if no data
beta.TREX[1+(k-1)*2] <- b.TREX[1+(k-1)*2]
* blnCovars[3] * nCo[4,1+(k-1)*2] # 'turn off' if no data
for (i in 1:4) {
b.Freq[i,1+(k-1)*2] ~ dnorm(0, .001) # priors for freq--response coeffs
beta.Freq[i,1+(k-1)*2] <- b.Freq[i,1+(k-1)*2] * blnCovars[4]
* step(i-2)
* nCo[5,1+(k-1)*2] # 'turn off' if ID=1 or no data
}
}
beta.PRN[2] <- (beta.PRN[1] + beta.PRN[3]) * nCo[1,2] # beta(0,2) = (0,1)+(1,2)
beta.Load[2] <- (beta.Load[1] + beta.Load[3]) * nCo[2,2] # beta(0,2) = (0,1)+(1,2)
beta.PRNX[2] <- (beta.PRNX[1] + beta.PRNX[3]) * nCo[3,2] # beta(0,2) = (0,1)+(1,2)
beta.TREX[2] <- (beta.TREX[1] + beta.TREX[3]) * nCo[4,2] # beta(0,2) = (0,1)+(1,2)
for (i in 1:4) {
beta.Freq[i,2] <- (beta.Freq[i,1] + beta.Freq[i,3])
* nCo[5,2] # beta(0,2) = (0,1)+(1,2)
}
}

# fit effect estimates without and with covariate effects
for (k in 1:3) {
for (j in 1:NumRx) {
d.fit[j,k] <- d[j,k]
}
for (c in 1:NumCovars) {
for (i in 1:NumCore) {
d.fit[NumRx+(c-1)*NumCore+i, k] <- d[core[i], k]
+ beta.PRN[k] * equals(c, 1)
+ beta.PRN[k] * equals(c, 2)
+ beta.Load[k] * equals(c, 2)
+ beta.TREX[k] * equals(c, 3)
+ beta.PRN[k] * equals(c, 4)
}
}
}

```

```

+ beta.Load[k] * equals(c, 4)
+ beta.PRNX[k] * equals(c, 4)
+ beta.Freq[betaID[core[i]], k] * equals(c, 5) * 1
+ beta.Freq[betaID[core[i]], k] * equals(c, 6) * 2
    }
  }
}

# generate final 'd's (set to null where no evidence)
for (j in 1:NumRx) {
  d[j,2] <- d[j,1] + d[j,3]
  d.final[j,1] <- d.fit[j,1] * nRx[j,1]
  nRxCo[j,1] <- nRx[j,1]
  for (k in 2:3) {
    nRxCo[j,k] <- nRx[j,3]
    d.final[j,k] <- d.fit[j,k] * nRx[j,3]
  }
}

for (c in 1:NumCovars) {
  for (i in 1:NumCore) {
    for (k in 1:3) {
      nRxCo[NumRx+(c-1)*NumCore+i,k] <- nRx[core[i],k] * nCo[c,k]
      d.final[NumRx+(c-1)*NumCore+i,k] <- d.fit[NumRx+(c-1)*NumCore+i,k]
        * nRxCo[NumRx+(c-1)*NumCore+i,k]
    }
  }
}

# Estimates of absolute treatment effects, given baseline
for (k in 1:2) {
  precA[k] <- pow(SDA[k], -2)
  predPrecA[k] <- pow(predSDA[k], -2)
  AMean[k] ~ dnorm(meanA[k], precA[k])
  APred[k] ~ dnorm(predA[k], predPrecA[k])
}

Tmean[1,1] <- AMean[1] * (ASMD.SD[1] * blnSMD + (1-blnSMD))
Tmean[1,2] <- AMean[2] * (ASMD.SD[2] * blnSMD + (1-blnSMD))
Tpred[1,1] <- AMean[1] * (ASMD.SD[1] * blnSMD + (1-blnSMD))
Tpred[1,2] <- AMean[2] * (ASMD.SD[2] * blnSMD + (1-blnSMD))
Tmean[1,3] <- Tmean[1,2] - Tmean[1,1]
Tpred[1,3] <- Tpred[1,2] - Tpred[1,1]
for (j in 2:NumRx+NumCore*NumCovars) {
  for (k in 1:2) {
    Tmean[j,k] <- AMean[k] * (1-equals(d.final[j,k], 0))
      + d.final[j,k] * (ASMD.SD[k] * blnSMD + (1-blnSMD))
    Tpred[j,k] <- APred[k] * (1-equals(d.final[j,k], 0))
      + d.final[j,k] * (ASMD.SD[k] * blnSMD + (1-blnSMD))
  }
  Tmean[j,3] <- (Tmean[j,2] - Tmean[j,1]) * (1-equals(d.final[j,2], 0))
  Tpred[j,3] <- (Tpred[j,2] - Tpred[j,1]) * (1-equals(d.final[j,2], 0))
}

for (k in 1:3) {
  # pairwise MDs for all possible pair-wise comparisons
  for (c in 1:(NumRx+NumCore*NumCovars-1)) {
    for (j in (c+1):NumRx+NumCore*NumCovars) {
      MD[c,j,k] <- (d.final[j,k] - d.final[c,k]) * nRxCo[j,k] * nRxCo[c,k]
    }
  }

  # ranking on relative scale
  for (j in 1:NumRx+NumCore*NumCovars) {
    rk[j,k] <- blnHiGood*(NumRx+NumCore*NumCovars+1-rank(d.toRank[,k],j))
      + (1-blnHiGood)*rank(d.toRank[,k],j)
    best[j,k] <- equals(rk[j,k],1) # prob. that treat j is best
    for (h in 1:NumRx+NumCore*NumCovars) {
      pRk[h,j,k] <- equals(rk[j,k],h) # prob. that treat j is hth best
    }
  }
}

# values for ranking (set to -999 if no evidence)
for (c in 1:NumRx) {
  d.toRank[c,1] <- d.final[c,1] + (1-nRx[c,1])*-999
  for (k in 2:3) {
    d.toRank[c,k] <- d.final[c,k] + (1-nRx[c,3])*-999
  }
}

for (k in 1:3) {
  for (c in 1:NumCovars) {
    for (i in 1:NumCore) {
      d.toRank[NumRx+(c-1)*NumCore+i,k] <- d.final[NumRx+(c-1)*NumCore+i,k] * nCo[c,k]
        + (1-nCo[c,k])*-999
    }
  }
}

# establish which treatments have evidence
for (l in 1:NumRx) {
  for (i in 1:NumStudies) {

```

```

for (j in 1:NumArms[i]) {
  nnnRx[l,i,j,1] <- equals(Rx[i,j,1], 1)
}
nnRx[l,i,1] <- sum(nnnRx[l,i,1:NumArms[i],1])
}
for (i in NumStudies.0_12only+1:NumStudies) {
  for (j in 1:NumArms[i]) {
    nnnRx[l,i,j,3] <- equals(Rx[i,j,3], 1)
  }
  nnRx[l,i,3] <- sum(nnnRx[l,i,1:NumArms[i],3])
}
nRx[l,1] <- step(sum(nnRx[l,1:NumStudies,1])-1)
nRx[l,3] <- step(sum(nnRx[l,NumStudies.0_12only+1:NumStudies,3])-1)
nRx[l,2] <- nRx[l,1] * nRx[l,3]
}

# establish which covariates have evidence
for (i in 1:NumStudies.0_12only) {
  for (j in 1:NumArms[i]) {
    nnnCo[i,j,1,1] <- step(PRN[i,j,1]-1)
    nnnCo[i,j,2,1] <- step(Load[i,j,1]-1)
    nnnCo[i,j,3,1] <- step(TREX[i,j,1]-1)
    nnnCo[i,j,4,1] <- step(PRNx[i,j,1]-1)
    nnnCo[i,j,5,1] <- step(Freq[i,j,1]-1.01)
    nnnCo[i,j,6,1] <- step(Freq[i,j,1]-1.01)
  }
  for (c in 1:6) {
    nnCo[i,c,1] <- sum(nnnCo[i,1:NumArms[i],c,1])
    nnCo[i,c,3] <- 0
  }
}
for (i in NumStudies.0_12only+1:NumStudies) {
  for (k in 1:2) {
    for (j in 1:NumArms[i]) {
      nnnCo[i,j,1,1+(k-1)*2] <- step(PRN[i,j,1+(k-1)*2]-1)
      nnnCo[i,j,2,1+(k-1)*2] <- step(Load[i,j,1+(k-1)*2]-1)
      nnnCo[i,j,3,1+(k-1)*2] <- step(TREX[i,j,1+(k-1)*2]-1) * equals(k, 1)
      nnnCo[i,j,4,1+(k-1)*2] <- step(PRNx[i,j,1+(k-1)*2]-1) * equals(k, 1)
      nnnCo[i,j,5,1+(k-1)*2] <- step(Freq[i,j,1+(k-1)*2]-1.01)
      nnnCo[i,j,6,1+(k-1)*2] <- step(Freq[i,j,1+(k-1)*2]-1.01)
    }
    for (c in 1:6) {
      nnCo[i,c,1+(k-1)*2] <- sum(nnnCo[i,1:NumArms[i],c,1+(k-1)*2])
    }
  }
}
for (c in 1:6) {
  nCo[c,1] <- step(sum(nnCo[1:NumStudies,c,1])-1)
  nCo[c,3] <- step(sum(nnCo[NumStudies.0_12only+1:NumStudies,c,3])-1)
  nCo[c,2] <- nCo[c,1] * nCo[c,3]
}
nCo[1,1,99] <- 0 # dummy data to stop BUGS tripping over when numCovars == 0
nCo[1,99] <- 0 # dummy data to stop BUGS tripping over when numCovars == 0
}

```

G.4.1.25 Categorical data

56 Binomial model with probit link, with provision for meta-regression (inter-study 57 random effects; inter-category random effects)

```

# Binomial likelihood, probit link (ordered categorical data)
# Fixed effects model for multi-arm trials
# based on
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
# NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework
# for Pairwise and Network Meta-Analysis of Randomised Controlled Trials.
# 2011; last updated September 2016.
# and
# Dias, S., Sutton, A.J., Welton, N.J. & Ades, A.E.
# NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression,
# bias and bias-adjustment. 2011; last updated April 2012.
# http://www.nicedsu.org.uk
#
# This model will include covariates if numCovars is set to > 1 and blnCovars != c(0,0,0,0)
# blnCovars[1] is a switch for PRN
# blnCovars[2] is a switch for Load
# blnCovars[3] is a switch for TREX and PRNX
# blnCovars[4] is a switch for Frequency
# Outputs are calculated with and without covariates for treatments identified in core c()

model {
  for(i in 1:NumStudies) {
    w[i,1] <- 0 # indexes studies
    delta[i,1] <- 0 # multi-arm adjustment =0 for control arm
    mu[i] ~ dnorm(0, .0001) # treatment effect =0 for control arm
    zeta[i,1] <- 0 # vague priors for all trial baselines
    # z-score is 0 for bottom category
  }
}

```

```

for (c in 2:maxNumCats-1) {
  zeta.sd[i,c] <- sqrt(log(1+(pow(z.sd,2)/pow(z.aux[c],2))))
  # calculate SD of lognorm dist
  zeta.mean[i,c] <- log(z.aux[c]) - 0.5 * pow(zeta.sd[i,c],2)
  # calculate mean of lognorm dist
  zeta.prec[i,c] <- pow(zeta.sd[i,c],-2) # convert SD to precision
  zeta.aux[i,c] ~ dlnorm(zeta.mean[i,c], zeta.prec[i,c])
  # interval between z-scores
  zeta[i,c] <- zeta[i,c-1] + zeta.aux[i,c]
  # add interval to prev z-score to get new one
}
for (j in 1:NumArms[i]) {
  # indexes arms
  p[i,j,1] <- 1 # Pr(score>0 = 1)
  for (c in 1:numCats[i]-1) {
    # indexes categories
    n[i,j,c] <- N[i,j] - sum(r[i,j,1:c]) + r[i,j,c]
    r[i,j,c] ~ dbin(q[i,j,c], n[i,j,c]) # binomial likelihood
    q[i,j,c] <- 1-(p[i,j,C[i,c+1]]/p[i,j,C[i,c]])
    # conditional probabilities

    theta[i,j,c] <- mu[i]
      + delta[i,j]
      + zeta[i,C[i,c+1]-1]
      + beta.PRN * (PRN[i,j] - PRN[i,1])
      + beta.Load * (Load[i,j]*PRN[i,j] - Load[i,1]*PRN[i,1])
      + beta.TREX * (TREX[i,j] - TREX[i,1])
      + beta.PRNX * (PRNX[i,j] - PRNX[i,1])
      + (beta.Freq[betaID[Rx[i,j]]] * Freq[i,j])
      - (beta.Freq[betaID[Rx[i,1]]] * Freq[i,1])
    # linear predictor
    rhat[i,j,c] <- q[i,j,c] * n[i,j,c] # predicted number events
    dv[i,j,c] <- 2 * (r[i,j,c]*(log(r[i,j,c]) - log(rhat[i,j,c]))
      +(n[i,j,c] - r[i,j,c]) * (log(n[i,j,c]-r[i,j,c])
      - log(n[i,j,c] - rhat[i,j,c])))
    # deviance contribution
  }
  dev[i,j] <- sum(dv[i,j,1:numCats[i]-1]) # close category loop
  # deviance contribution of each arm
  for (c in 2:numCats[i]) {
    # indexes categories
    p[i,j,C[i,c]] <- 1 - phi(theta.adj[i,j,c])
    # link function
    theta.adj[i,j,c] <- step(-5-theta[i,j,c-1]) * -5
      + step(theta[i,j,c-1]-5) * 5
      + step(5-theta[i,j,c-1]) * step(theta[i,j,c-1]+5)
      * theta[i,j,c-1] # adjust phi(x) for values that can give
    # numerical errors when x< -5, phi(x)=0,
    # when x> 5, phi(x)=1
  }
  # close category loop
  # close arm loop
  for (j in 2:NumArms[i]) {
    # indexes arms
    delta[i,j] ~ dnorm(md[i,j], taud[i,j]) # trial-specific MD distributions
    md[i,j] <- d[Rx[i,j]] - d[Rx[i,1]] + sw[i,j]
    # mean of MD dists, with MAC
    taud[i,j] <- tau * 2 * (j-1) / j # precision of MD dists, with MAC
    w[i,j] <- (delta[i,j] - d[Rx[i,j]] + d[Rx[i,1]]) # adjustment, multi-arm RCTs
    # multi-arm correction ("MAC")
    sw[i,j] <- sum(w[i,1:j-1]) / (j-1) # cumulative MAC
  }
  # close arm loop
  resdev[i] <- sum(dev[i,1:NumArms[i]]) # summed residual deviance for this trial
}
# close trial loop
totresdev <- sum(resdev[]) # total residual deviance

z[1] <- 0 # set z=0 for bottom category
for (j in 2:maxNumCats-1) {
  # indexes all categories
  z.aux[j] ~ dunif(0,5) # vague priors for inter-categories intervals
  z[j] <- z[j-1] + z.aux[j] # z-score = prev z-score plus interval
}
# close category loop
z.sd ~ dunif(0, 2) # vague prior for between-trial z SD
z.prec <- pow(z.sd, -2) # between-trial z precision

d[1] <- 0 # effect is zero for reference treatment
for (j in 2:NumRx) {
  # indexes treatments
  d[j] ~ dnorm(0, .0001) # vague priors for treatment effects
}
sdu ~ dunif(RFXpriorParam1, RFXpriorParam2) # uniform between-trial prior
sdn ~ dnorm(RFXpriorParam1, RFXpriorParam2) # normal between-trial prior
sdl ~ dlnorm(RFXpriorParam1, RFXpriorParam2) # lognormal between-trial prior
sd <- sdu * equals(RFXpriorD,1)
  + sdn * equals(RFXpriorD,2)
  + sdl * equals(RFXpriorD,3) # choose desired between-trial prior
tau <- pow(sd, -2) # between-trial precision

# covariates
b.PRN ~ dnorm(0, .001)
b.Load ~ dnorm(0, .001)
b.TREX ~ dnorm(0, .001)
b.PRNX ~ dnorm(0, .001)
beta.PRN <- b.PRN * blnCovars[1]
beta.Load <- b.Load * blnCovars[2]
beta.TREX <- b.TREX * blnCovars[3]
beta.PRNX <- b.PRNX * blnCovars[3]
beta.Freq[1] <- 0
for (i in 2:3) {

```

```

b.Freq[i] ~ dnorm(0, .001)
beta.Freq[i] <- b.Freq[i] * blnCovars[4]
}
# hardcoded IDs for frequency covariates
betaID[1] <- 3
betaID[2] <- 1
betaID[3] <- 1
betaID[4] <- 2
betaID[5] <- 3
betaID[6] <- 1
betaID[7] <- 1

#effect estimates without and with covariate effects
for (c in 1:NumRx) {
  dd[c] <- d[c]
}
for (c in 1:NumCovars) {
  for (i in 1:NumCore) {
    dd[NumRx+(c-1)*NumCore+i] <- d[core[i]]
      + beta.PRN * equals(c, 1)
      + beta.PRN * equals(c, 2)
      + beta.Load * equals(c, 2)
      + beta.TREX * equals(c, 3)
      + beta.PRN * equals(c, 4)
      + beta.Load * equals(c, 4)
      + beta.PRN * equals(c, 4)
      + beta.Freq[betaID[core[i]]] * equals(c, 5) * 1
      + beta.Freq[betaID[core[i]]] * equals(c, 6) * 2
  }
}

# Provide estimates of treatment effects T[j] on the natural (probability) scale
precA <- pow(SDA, -2)
predPrecA <- pow(predSDA, -2)
AMean ~ dnorm(meanA, precA)
APred ~ dnorm(predA, predPrecA)
for (i in 1:(NumRx+NumCore*NumCovars)) {
  for (j in 1:maxNumCats-1) {
    Tmean[i,j] <- 1 - phi(AMean + dd[i] + z[j])
    Tpred[i,j] <- 1 - phi(APred + dd[i] + z[j])
  }
}

# pairwise z-scores for all possible pair-wise comparisons
for (i in 1:((NumRx+NumCore*NumCovars)-1)) {
  for (j in (i+1):NumRx+NumCore*NumCovars) {
    pairZ[i,j] <- dd[j] - dd[i]
  }
}

# ranking on relative scale
for (j in 1:NumRx+NumCore*NumCovars) {
  rk[j] <- blnHiGood*(NumRx+NumCore*NumCovars+1-rank(dd[,j]))
    + (1-blnHiGood)*rank(dd[,j])
  best[j] <- equals(rk[j],1) # prob that treat j is best
  for (h in 1:NumRx+NumCore*NumCovars) {
    pRk[h,j] <- equals(rk[j],h) # prob that treat j is hth best
  }
}
}

# *** PROGRAM ENDS

```

G.4.1.81 Dichotomous data

Binomial model with logit link, with provision for meta-regression (random effects)

```

# Binomial likelihood, logit link
# Random-effects model for multi-arm trials
# based on
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
# NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework
# for Pairwise and Network Meta-Analysis of Randomised Controlled Trials.
# 2011; last updated September 2016.
# and
# Dias, S., Sutton, A.J., Welton, N.J. & Ades, A.E.
# NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression,
# bias and bias-adjustment. 2011; last updated April 2012.
# http://www.nicedsu.org.uk
#
# This model will include covariates if numCovars is set to > 1 and blnCovars != c(0,0,0)
# blnCovars[1] is a switch for PRN
# blnCovars[2] is a switch for Load
# blnCovars[3] is a switch for TREX and PRNX
# blnCovars[4] is a switch for Frequency
# Outputs are calculated with and without covariates for treatments identified in core c()

model {
  for(i in 1:NumStudies) {
    # indexes studies

```

```

mu[i] ~ dnorm(0, .0001) # vague priors for all trial baselines
delta[i,1] <- 0 # effect is zero for control arm
w[i,1] <- 0 # multi-arm adjustment = zero for ctrl
for (j in 1:NumArms[i]) { # indexes arms
  k[i,j] ~ dbin(p[i,j],N[i,j]) # binomial likelihood
  logit(p[i,j]) <- mu[i]
    + delta[i,j]
    + beta.PRN * (PRN[i,j] - PRN[i,1])
    + beta.TREX * (TREX[i,j] - TREX[i,1])
    + beta.PRNX * (PRNX[i,j] - PRNX[i,1])
    + beta.Load * (Load[i,j]*PRN[i,j] - Load[i,1]*PRN[i,1])
    + (beta.Freq[betaID[Rx[i,j]]] * Freq[i,j])
    - (beta.Freq[betaID[Rx[i,1]]] * Freq[i,1])
  rhat[i,j] <- p[i,j] * N[i,j] # linear predictor with covariates
  dev[i,j] <- 2 * (k[i,j] * (log(k[i,j])-log(rhat[i,j]))) # expected value of the numerators
    + (N[i,j]-k[i,j]) * (log(N[i,j]-k[i,j]) - log(N[i,j]-rhat[i,j]))) # deviation contribution
} # close arm loop
for (j in 2:NumArms[i]) { # indexes arms
  delta[i,j] ~ dnorm(md[i,j],taud[i,j]) # trial-specific LOR distributions
  md[i,j] <- d[Rx[i,j]] - d[Rx[i,1]] + sw[i,j] # mean of LOR distributions (with MAC)
  taud[i,j] <- tau * 2*(j-1)/j # precision of LOR distributions (with MAC)
  w[i,j] <- (delta[i,j] - d[Rx[i,j]] + d[Rx[i,1]])
  sw[i,j] <- sum(w[i,1:j-1])/(j-1) # multi-arm correction ("MAC")
} # cumulative MAC
resdev[i] <- sum(dev[i,1:NumArms[i]]) # close arm loop
# summed deviance contribution
# close study loop
totresdev <- sum(resdev[]) # total residual deviance

d[1]<-0 # effect is 0 for reference treatment
for (j in 2:NumRx) { # indexes treatments
  d[j] ~ dnorm(0, .0001) # vague priors for treatment effects
} # close treatment loop
sdu ~ dunif(RFXpriorParam1, RFXpriorParam2) # uniform between-trial prior
sdn ~ dnorm(RFXpriorParam1, RFXpriorParam2) # normal between-trial prior
sdl ~ dlnorm(RFXpriorParam1, RFXpriorParam2) # lognormal between-trial prior
sd <- sdu * equals(RFXpriorD,1)
  + sdn * equals(RFXpriorD,2)
  + sdl * equals(RFXpriorD,3) # select correct between-trial prior
tau <- pow(sd,-2) # between-trial precision

# covariates
b.PRN ~ dnorm(0, .001)
b.Load ~ dnorm(0, .001)
b.TREX ~ dnorm(0, .001)
b.PRNX ~ dnorm(0, .001)
beta.PRN <- b.PRN * blnCovars[1]
beta.Load <- b.Load * blnCovars[2]
beta.TREX <- b.TREX * blnCovars[3]
beta.PRNX <- b.PRNX * blnCovars[3]
beta.Freq[1] <- 0
for (i in 2:3) {
  b.Freq[i] ~ dnorm(0, .001)
  beta.Freq[i] <- b.Freq[i] * blnCovars[4]
}
# hardcoded IDs for frequency covariates
betaID[1] <- 3
betaID[2] <- 1
betaID[3] <- 1
betaID[4] <- 2
betaID[5] <- 3
betaID[6] <- 1
betaID[7] <- 1

#effect estimates without and with covariate effects
for (c in 1:NumRx) {
  dd[c] <- d[c]
}
for (c in 1:NumCovars) {
  for (i in 1:NumCore) {
    dd[NumRx+(c-1)*NumCore+i] <- d[core[i]]
      + beta.PRN * equals(c, 1)
      + beta.PRN * equals(c, 2)
      + beta.Load * equals(c, 2)
      + beta.TREX * equals(c, 3)
      + beta.PRN * equals(c, 4)
      + beta.Load * equals(c, 4)
      + beta.PRNX * equals(c, 4)
      + beta.Freq[betaID[core[i]]] * equals(c, 5) * 1
      + beta.Freq[betaID[core[i]]] * equals(c, 6) * 2
  }
}

# Provide estimates of treatment effects T[j] on the natural (probability) scale
precA <- pow(SDA, -2)
predPrecA <- pow(predSDA, -2)
AMean ~ dnorm(meanA, precA)
APred ~ dnorm(predA, predPrecA)

```

```

21 for (j in 1:(NumRx+NumCore*NumCovars)) {
22   logit(Tmean[j]) <- AMean + dd[j]
23   logit(Tpred[j]) <- APred + dd[j]
24 }
25 # pairwise ORs and LORs for all possible pair-wise comparisons
26 for (c in 1:((NumRx+NumCore*NumCovars)-1)) {
27   for (j in (c+1):(NumRx+NumCore*NumCovars)) {
28     LOR[c,j] <- (dd[j] - dd[c])
29     OR[c,j] <- exp(LOR[c,j])
30   }
31 }
32 # ranking on relative scale
33 for (j in 1:(NumRx+NumCore*NumCovars)) {
34   rk[j] <- blnHiGood*((NumRx+NumCore*NumCovars)+1-rank(dd[,j])) + (1-blnHiGood)*rank(dd[,j])
35   best[j] <- equals(rk[j],1) # probability that treat j is best
36   for (h in 1:(NumRx+NumCore*NumCovars)) {
37     pRk[h,j] <- equals(rk[j],h) # probability that treat j is hth best
38   }
39 }

```

G.4.2.3 Baseline syntheses

G.4.2.24 Continuous data

25 Bivariate normal model for 1- and 2-year data (random effects)

```

26 # Baseline model for continuous data
27 # multivariate normal likelihood, identity link
28 # based on
29 # Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
30 # NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework
31 # for Pairwise and Network Meta-Analysis of Randomised Controlled Trials.
32 # 2011; last updated September 2016.
33 # and
34 # Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
35 # NICE DSU Technical Support Document 5: Evidence synthesis in the baseline
36 # natural history model. 2011.
37 # http://www.nicedsu.org.uk
38
39 model {
40   for(i in 1:NumStudies.0_12only) { # indexes studies
41     se[i,1] <- SD[i,1] / sqrt(N[i,1]) # calculate SEs
42     prec[i] <- pow(se[i,1], -2) # set precisions
43     mu[i,1] ~ dnorm(m[1], tau[1]) # trial-specific baseline with random effects
44     MC[i,1] ~ dnorm(p[i], prec[i]) # normal likelihood
45     p[i] <- mu[i,1] # identity link
46   }
47   for(i in NumStudies.0_12only+1:NumStudies) { # indexes studies with 0-24 data
48     MC[i,1:2] ~ dnorm(phi[i,1:2], mvnPrec[i,,]) # mvnormal likelihood
49     vcov[i,1,1] <- var[i,1] # vcov[1,1]
50     vcov[i,2,1] <- var[i,1] # vcov[2,1]
51     vcov[i,1,2] <- var[i,1] # vcov[1,2]
52     vcov[i,2,2] <- var[i,2] # vcov[2,2]
53     mvnPrec[i,1:2,1:2] <- inverse(vcov[i,,]) # convert vcov matrix to precision
54     for (k in 1:2) { # indexes timepoints
55       se[i,k] <- SD[i,k] / sqrt(N[i,k]) # calculate SEs
56       var[i,k] <- pow(se[i,k], 2) # set variances
57       mu[i,k] ~ dnorm(m[k], tau[k]) # trial-specific baseline with random effects
58       phi[i,k] <- mu[i,k] # identity link
59     }
60   } # close study loop
61   for (k in 1:2) {
62     sd[k] ~ dunif(0, 5) # vague prior for SD (baseline)
63     tau[k] <- pow(sd[k], -2) # between-trial precision (baseline)
64     m[k] ~ dnorm(0, .0001) # vague prior for mean (baseline)
65     prob[k] <- m[k] # posterior mean
66     mu.new[k] ~ dnorm(m[k], tau[k]) # pred. dist. for baseline
67     pred[k] <- mu.new[k] # predictive mean for a new observation
68   }
69 }

```

G.4.2.71 Categorical data

72 Binomial model with probit link (inter-study random effects; inter-category random effects)

```

73 # Binomial likelihood, probit link (different categories)
74 # Fixed-effects baseline model
75
76

```

```

# based on
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
# NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework
# for Pairwise and Network Meta-Analysis of Randomised Controlled Trials.
# 2011; last updated September 2016.
# and
# Dias, S., Welton, N.J., Sutton, A.J., Ades, A.E.
# NICE DSU Technical Support Document 5: Evidence synthesis in the baseline
# natural history model. 2011.
# http://www.nicedsu.org.uk

model {
  for(i in 1:NumStudies) {
    mu[i] ~ dnorm(m, tau.m) # indexes studies
    zeta[i,1] <- 0 # trial-specific baseline with random FX
    # z-score is 0 for bottom category
    for (c in 2:maxNumCats-1) { # indexes categories in trial
      zeta.sd[i,c] <- sqrt(log(1+(pow(z.sd,2)/pow(z.aux[c],2))))
      # calculate SD of lognorm dist
      zeta.mean[i,c] <- log(z.aux[c]) - 0.5 * pow(zeta.sd[i,c],2)
      # calculate mean of lognorm dist
      zeta.prec[i,c] <- pow(zeta.sd[i,c],-2) # convert SD to precision
      zeta.aux[i,c] ~ dlnorm(zeta.mean[i,c], zeta.prec[i,c])
      # interval between z-scores
      zeta[i,c] <- zeta[i,c-1] + zeta.aux[i,c]
      # add interval to prev z-score to get new one
    }
    # close category loop
    p[i,1] <- 1 # Pr(score>0 = 1)
    for (c in 1:numCats[i]-1) { # indexes categories
      n[i,c] <- N[i] - sum(r[i,1:c]) + r[i,c] # calculate category-specific ns
      r[i,c] ~ dbin(q[i,c], n[i,c]) # binomial likelihood
      q[i,c] <- 1 - (p[i,C[i,c+1]] / p[i,C[i,c]])
      # conditional probabilities
      theta[i,c] <- mu[i] + zeta[i,C[i,c+1]-1] # linear predictor
    }
    # close category loop
    for (c in 2:numCats[i]) { # indexes categories
      p[i,C[i,c]] <- 1 - phi(theta.adj[i,c]) # link function
      theta.adj[i,c] <- step(-5-theta[i,c-1]) * -5
        + step(theta[i,c-1]-5) * 5
        + step(5-theta[i,c-1]) * step(theta[i,c-1]+5)
      # adjust phi(x) for values that can give
      # numerical errors when x< -5, phi(x)=0,
      # when x> 5, phi(x)=1
    }
    # close category loop
  }
  # close study loop
  z[1] <- 0 # set z=0 for bottom category
  for (j in 2:maxNumCats-1) { # indexes all categories
    z.aux[j] ~ dunif(0,5) # vague priors for inter-categories intervals
    z[j] <- z[j-1] + z.aux[j] # z-score = prev z-score plus interval
  }
  # close category loop
  z.sd ~ dunif(0, 2) # vague prior for between-trial z SD
  z.prec <- pow(z.sd, -2) # between-trial z precision
  sd.m ~ dunif(0, 5) # vague prior for SD (baseline)
  tau.m <- pow(sd.m, -2) # between-trial precision (baseline)
  m ~ dnorm(0, .0001) # vague prior for mean (baseline)
  prob <- step(5+m) * (step(m-5) + step(5-m)) * phi(m)
  # posterior probability (response = cat1)
  mu.new ~ dnorm(m, tau.m) # pred. dist. for baseline (log-hazard)
  pred <- step(5+mu.new) * (step(mu.new-5) + step(5-mu.new)) * phi(mu.new)
  # predictive probability (response = cat1)
}

```

G.4.2.81 Dichotomous data

Binomial model with logit link (random effects)

```

# Baseline model for dichotomous data
# binomial likelihood, logit link
# based on
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
# NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework
# for Pairwise and Network Meta-Analysis of Randomised Controlled Trials.
# 2011; last updated September 2016.
# and
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
# NICE DSU Technical Support Document 5: Evidence synthesis in the baseline
# natural history model. 2011.
# http://www.nicedsu.org.uk

model {
  for(i in 1:NumStudies) {
    k[i] ~ dbin(p[i], N[i]) # indexes studies
    logit(p[i]) <- mu[i] # binomial likelihood
    mu[i] ~ dnorm(m, tau.m) # model for linear predictor
  }
  # trial-specific baseline with random effects
  # close study loop
  sd.m ~ dunif(0, 5) # vague prior for SD (baseline)
  tau.m <- pow(sd.m, -2) # between-trial precision (baseline)
  m ~ dnorm(0, .0001) # vague prior for mean (baseline)
}

```



```
1 logit(prob) <- m # posterior probability of response
2 mu.new ~ dnorm(m, tau.m) # pred. dist. for baseline (log-odds)
3 logit(pred) <- mu.new # predictive probability of response
4 }
5
6 NICE 2017
```